COX

Cyclooxygenase

Cyclooxygenase (COX), officially known as prostaglandin-endoperoxide synthase (PTGS), is an enzyme that is responsible for formation of important biological mediators called prostanoids, including prostaglandins, prostacyclin and thromboxane. Pharmacological inhibition of COX can provide relief from the symptoms of inflammation and pain. Drugs, like Aspirin, that inhibit cyclooxygenase activity have been available to the public for about 100 years. Two cyclooxygenase isoforms have been identified and are referred to as COX-1 and COX-2. Under many circumstances the COX-1 enzyme is produced constitutively (i.e., gastric mucosa) whereas COX-2 is inducible (i.e., sites of inflammation). Non-steroidal anti-inflammatory drugs (NSAID), such as aspirin and ibuprofen, exert their effects through inhibition of COX. The main COX inhibitors are the non-steroidal anti-inflammatory drugs (NSAIDs).

(+)-Catechin hydrate

Cat. No.: HY-N0355

(+)-Catechin hydrate inhibits cyclooxygenase-1 (**COX-1**) with an IC_{50} of 1.4 μM.



Purity: 99.59%
Clinical Data: Phase 4
Size: 100 mg

(+/-)-Catechin Gallate-13C3

Cat. No.: HY-N0356S

(+/-)-Catechin Gallate-13C3 is the 13C-labeled (-)-Catechin gallate. (-)-Catechin gallate is a minor constituent in green tea catechins. (-)-Catechin gallate inhibits the activity of **COX-1** and **COX-2** enzymes.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(-)-Catechin

((-)-Cianidanol; (-)-Catechuic acid)

Cat. No.: HY-N0898A

(-)-Catechin is an isomer of Catechin having a trans 2S,3R configuration at the chiral center. Catechin inhibits cyclooxygenase-1 (COX-1) with an IC_{50} of 1.4 μM.



Purity: 98.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

(-)-Catechin gallate

((-)-Catechin 3-gallate; (-)-Catechin 3-O-gallate)

Cat. No.: HY-N0356

(-)-Catechin gallate is a minor constituent in green tea catechins. (-)-Catechin gallate inhibits the activity of **COX-1** and **COX-2** enzymes.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

(-)-Epicatechin

((-)-Epicatechol; Epicatechin; epi-Catechin)

Cat. No.: HY-N0001

(-)-Epicatechin inhibits cyclooxygenase-1 (**COX-1**) with an IC_{50} of 3.2 μM. (-)-Epicatechin inhibits the IL-1β-induced expression of iNOS by blocking the nuclear localization of the p65 subunit of NF-κB.



Purity: 99.0%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

(-)-Epicatechin gallate

(Epicatechin gallate; ECG; (-)-Epicatechin 3-O-gallate)

Cat. No.: HY-N0002

(-)-Epicatechin gallate (Epicatechin gallate) inhibits cyclooxygenase-1 (**COX-1**) with an IC_{50} of 7.5 μM.



Purity: 98.57%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

(E)-Ethyl p-methoxycinnamate

Cat. No.: HY-N0346A

(E)-Ethyl p-methoxycinnamate is a natural product found in Kaempferia galangal with anti-inflammatory, anti-neoplastic and anti-microbial effects.



Purity: 99.39%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

(R)-(-)-Etodolac-d3

Cat. No.: HY-76251S

(R)-(-)-Etodolac-d3 is the deuterium labeled Etodolac. Etodolac (AY-24236) is a non-steroidal anti-inflammatory compound that is a non-selective inhibitor of COX (IC_{50}=53.5 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

(rac)-Etodolac-d3

Cat. No.: HY-76251S1

(Rac)-Etodolac-d3 ((Rac)-AY-24236-d3) is a labelled racemic Etodolac. Etodolac (AY-24236) is a non-steroidal anti-inflammatory compound that is a non-selective inhibitor of COX (IC_{50}=53.5 nM).



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

(Rac)-γ-Tocopherol

(DMPBQ)

Cat. No.: HY-115742

(Rac)-γ-Tocopherol (DMPBQ) is a Vitamin E isoform, which is converted by tocopherol cyclase to γ-Tcopherol.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(S)-(+)-Ibuprofen

((S)-Ibuprofen) Cat. No.: HY-78131A

(S)-(+)-Ibuprofen ((S)-Ibuprofen), a S(+)-enantiomer of Ibuprofen, is a potent **COX-1** and **COX-2** inhibitor with IC_{50}s of 2.1 μM and 1.6 μM, respectively. (S)-(+)-Ibuprofen has analgesic, anti-inflammatory, anticancer and antipyretic effects.



Purity: 99.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

(S)-(+)-Ibuprofen D3

((S)-Ibuprofen D3) Cat. No.: HY-78131AS

(S)-(+)-Ibuprofen D3 ((S)-Ibuprofen D3) is a deuterium labeled (S)-(+)-Ibuprofen. (S)-(+)-Ibuprofen is the S(+)-enantiomer of Ibuprofen that inhibits **COX-1** and **COX-2** activity with IC_{50}s of 2.1 μM and 1.6 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(S)-Flurbiprofen

(Esflurbiprofen) Cat. No.: HY-15123

(S)-Flurbiprofen is an active enantiomer of Flurbiprofen, with IC_{50} values of 0.48 μM and 0.47 μM for **COX-1** and **COX-2**, respectively.



Purity: 99.83%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 250 mg, 500 mg

(S)-Flurbiprofen-d3

(Esflurbiprofen-d3) Cat. No.: HY-15123S

(S)-Flurbiprofen-d3 (Esflurbiprofen-d3) is the deuterium labeled (S)-Flurbiprofen. (S)-Flurbiprofen is an active enantiomer of Flurbiprofen, with IC_{50} values of 0.48 μM and 0.47 μM for **COX-1** and **COX-2**, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(S)-Ketorolac

((-)-Ketorolac) Cat. No.: HY-B0580A

(S)-Ketorolac is a nonsteroidal anti-inflammatory agent. (S)-ketorolac exhibits potent **COX1** and **COX2** enzyme inhibition.



Purity: 99.62%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

(±)-Catechin

(rel-Cianidanol; rel-Catechuic acid) Cat. No.: HY-B1890

(±)-Catechin (rel-Cianidanol) is the racemate of Catechin. (±)-Catechin has two steric forms of (+)-Catechin and its enantiomer (-)-Catechin. (+)-Catechin inhibits cyclooxygenase-1 (COX-1) with an IC_{50} of 1.4 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

1-Hydroxy-ibuprofen

Cat. No.: HY-136592

1-Hydroxy Ibuprofen is a **metabolite** of Ibuprofen in P. australis. Ibuprofen is an anti-inflammatory inhibitor targeting **COX-1** and **COX-2** with IC_{50}s of 13 μM and 370 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

2,5-Di-tert-butylhydroquinone

Cat. No.: HY-W012399

2,5-Di-tert-butylhydroquinone (DTBHQ), the indirect food additive, regulates the activity of **5-lipoxygenase** as well as the activity of **COX-2** (IC_{50}=1.8 and 14.1 μM for 5-LO and COX-2, respectively) .



Purity: 99.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

2-Hydroxy Ibuprofen

((±)-2-Hydroxy Ibuprofen) Cat. No.: HY-126121

2-Hydroxy Ibuprofen is a metabolite of Ibuprofen. Ibuprofen is an anti-inflammatory inhibitor targeting COX-1 and COX-2 with IC_{50}s of 13 μM and 370 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

2-Hydroxy Ibuprofen-d6

((±)-2-Hydroxy Ibuprofen-d6) Cat. No.: HY-126121S

2-Hydroxy Ibuprofen-d6 ((±)-2-Hydroxy Ibuprofen-d6) is the deuterium labeled 2-Hydroxy Ibuprofen. 2-Hydroxy Ibuprofen is a metabolite of Ibuprofen. Ibuprofen is an anti-inflammatory inhibitor targeting COX-1 and COX-2 with IC_{50}s of 13 μM and 370 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

20(S)-Ginsenoside Rg3

(20(S)-Propanaxadiol; S-ginsenoside Rg3) Cat. No.: HY-N0603

20(S)-Ginsenoside Rg3 is the main component of Red ginseng. Ginsenoside Rg3 inhibits **Na**$^+$ and **hKv1.4** channel with IC_{50}s of 32.2±4.5 and 32.6±2.2 μM, respectively. 20(S)-Ginsenoside Rg3 also inhibits **Aβ** levels, **NF-κB** activity, and **COX-2** expression.



Purity: 98.10%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

3,3'-Diiodo-L-thyronine

(3,3'-T2) Cat. No.: HY-129974

3,3'-Diiodo-L-thyronine (3,3'-T2) is an **endogenous metabolite** of thyroid hormone. 3,3'-Diiodo-L-thyronine significantly enhances **COX** activity.



Purity: 98.21%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

3-Carene

Cat. No.: HY-N6663

3-Carene is a bicyclic monoterpene in essential oils extracted from pine trees. 3-Carene inhibits nociceptive stimulus-induced inflammatory infiltrates and COX-2 overexpression, and with antinociceptive effect.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

4,4'-Dihydroxy-2,6-dimethoxydihydrochalcone

Cat. No.: HY-N8184

4,4'-Dihydroxy-2,6-dimethoxydihydrochalcone exhibits **COX-1** and **COX-2** inhibitory activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

4-Methylamino antipyrine

Cat. No.: HY-135731

4-Methylamino antipyrine is an active metabolite of Metamizole. Metamizole is a pyrazolone non-steroidal anti-inflammatory drug (NSAID) and inhibits **COX**. Metamizole is an nonopioid analgesic drug and can be used for pain and fever.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 25 mg, 50 mg, 100 mg

4-Methylamino antipyrine hydrochloride

Cat. No.: HY-135731A

4-Methylamino antipyrine hydrochloride is an active metabolite of Metamizole. Metamizole is a pyrazolone non-steroidal anti-inflammatory drug (NSAID) and inhibits **COX**. Metamizole is an nonopioid analgesic drug and can be used for pain and fever.



Purity: >98%
Clinical Data: No Development Reported
Size: 25 mg, 50 mg, 100 mg

4-Methylamino antipyrine-d3 hydrochloride

Cat. No.: HY-135731AS

4-Methylamino antipyrine-d3 (hydrochloride) is deuterium labeled 4-Methylamino antipyrine (hydrochloride). 4-Methylamino antipyrine hydrochloride is an active metabolite of Metamizole.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

7,3',4'-Tri-O-methylluteolin

(5-Hydroxy-3',4',7-trimethoxyflavone) Cat. No.: HY-N7012

7,3',4'-Tri-O-methylluteolin (5-Hydroxy-3',4',7-trimethoxyflavone), a flavonoid compound, possesses potent anti-inflammatory effects in LPS-induced macrophage cell line mediated by inhibition of release of inflammatory mediators, NO, PGE2, and...



Purity: 99.28%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Aceclofenac

Cat. No.: HY-B0634

Aceclofenac is an orally active nonsteroidal anti-inflammatory drug (NSAID), with analgesic and anti-inflammatory properties. Aceclofenac is used for the research of osteoarthritis, ankylosing spondylitis, rheumatoid arthritis.



Purity: 99.75%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Aceclofenac-d4

Cat. No.: HY-B0634S

Aceclofenac-d4 is the deuterium labeled Aceclofenac. Aceclofenac is an orally active nonsteroidal anti-inflammatory drug (NSAID), with analgesic and anti-inflammatory properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Acemetacin

(TVX 1322)

Cat. No.: HY-B0482

Acemetacin (TVX 1322) is a non-steroidal anti-inflammatory drug and a glycolic acid ester of indometacin that is a cyclooxygenase inhibitor.



Purity: 99.97%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Acemetacin-d4

Cat. No.: HY-B0482S

Acemetacin-d4 is the deuterium labeled Acemetacin. Acemetacin (TVX 1322) is a non-steroidal anti-inflammatory drug and a glycolic acid ester of indometacin that is a cyclooxygenase inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Acetaminophen

(Paracetamol; 4-Acetamidophenol; 4'-Hydroxyacetanilide)

Cat. No.: HY-66005

Acetaminophen (Paracetamol) is a selective cyclooxygenase-2 (**COX-2**) inhibitor with an IC_{50} of 25.8 μM; is a widely used antipyretic and analgesic agent. Acetaminophen is a potent **hepatic N-acetyltransferase 2 (NAT2)** inhibitor.



Purity: 99.96%
Clinical Data: Launched
Size: 500 mg, 5 g, 10 g

Acetaminophen-13C6 (Paracetamol-13C6; 4-Acetamidophenol-13C6; 4'-Hydroxyacetanilide-13C6)

Cat. No.: HY-66005S3

Acetaminophen-13C6 (Paracetamol-13C6) is the 13C-labeled Acetaminophen. Acetaminophen (Paracetamol) is a selective cyclooxygenase-2 (**COX-2**) inhibitor with an IC_{50} of 25.8 μM; is a widely used antipyretic and analgesic agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Acetaminophen-d3 (Paracetamol-d3; 4-Acetamidophenol-d3; 4'-Hydroxyacetanilide-d3)

Cat. No.: HY-66005S1

Acetaminophen-d3 (Paracetamol-d3) is the deuterium labeled Acetaminophen. Acetaminophen (Paracetamol) is a selective cyclooxygenase-2 (**COX-2**) inhibitor with an IC_{50} of 25.8 μM; is a widely used antipyretic and analgesic agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Acetaminophen-d4

Cat. No.: HY-66005S

Acetaminophen-d4 is the deuterium labeled Acetaminophen. Acetaminophen (Paracetamol) is a selective cyclooxygenase-2 (**COX-2**) inhibitor with an IC_{50} of 25.8 μM; is a widely used antipyretic and analgesic agent. Acetaminophen is a potent **hepatic N-acetyltransferase 2 (NAT2)** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Adelmidrol

Cat. No.: HY-B1026

Adelmidrol exerts important anti-inflammatory effects that are partly dependent on **PPARγ**. Adelmidrol reduces **NF-κB** translocation, and **COX-2** expression.



Purity: ≥98.0%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 100 mg

AG-024322

Cat. No.: HY-15491

AG-024322 is a potent ATP-competitive pan-**CDK** inhibitor against cell cycle kinases **CDK1**, **CDK2**, and **CDK4** with K_i values in the 1-3 nM range. AG-024322 displays broad-spectrum anti-tumor activity and clear target modulation in vivo. AG-024322 induces cell **apoptosis**.



Purity: 98.69%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

Alminoprofen

(EB-382)

Cat. No.: HY-17485

Alminoprofen (EB-382) is a nonsteroidal anti-inflammatory drug (NSAID) of the phenylpropionic acid class. Alminoprofen possesses a dual anti-inflammatory action, by inhibiting both **secretory phospholipase A_2 ($sPLA_2$)** and **COX-2**.



Purity: 99.35%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg

Alminoprofen-d3

(EB-382-d3)

Cat. No.: HY-17485S

Alminoprofen-d3 (EB-382-d3) is the deuterium labeled Alminoprofen. Alminoprofen (EB-382) is a nonsteroidal anti-inflammatory drug (NSAID) of the phenylpropionic acid class.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Amfenac Sodium Hydrate

Cat. No.: HY-17479A

Amfenac Sodium Hydrate is a **COX-2** inhibitor.



Purity: 98.65%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Ampiroxicam

(CP 65703)

Cat. No.: HY-17484

Ampiroxicam(CP65703) is a nonselective cyclooxygenase inhibitor uesd as anti-inflammatory drug. Target: COX Ampiroxicam is a non-steroidal anti-inflammatory drug. It is a prodrug of piroxicam.



Purity: 97.12%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Ampyrone

(4-Aminoantipyrine)

Cat. No.: HY-B1398

Ampyrone is a reagent for glucose determination in the presence of peroxidase and phenol.



Purity: 98.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg, 1 g

Ampyrone-d3

(4-Aminoantipyrine-d3)

Cat. No.: HY-B1398S

Ampyrone-d3 (4-Aminoantipyrine-d3) is the deuterium labeled Ampyrone. Ampyrone is a reagent for glucose determination in the presence of peroxidase and phenol.



Purity: >98%
Clinical Data: No Development Reported
Size: 2.5 mg, 25 mg

Anemarsaponin B

Cat. No.: HY-N0811

Anemarsaponin B is a steroidal saponin. Anemarsaponin B decreases the protein and mRNA levels of **iNOS** and **COX-2**. Anemarsaponin B reduces the expressions and productions of pro-inflammatory cytokines, including TNF-a and IL-6.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Anti-inflammatory agent 10

Cat. No.: HY-115922

Anti-inflammatory agent 10 (compound 30) is a tilomisole-based benzimidazothiazole derivative. Anti-inflammatory agent 10 expresses activity on COX-2 enzyme more than COX-1. Anti-inflammatory agent 10 is orally active.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Anti-inflammatory agent 8

Cat. No.: HY-115920

Anti-inflammatory agent 8 (compound 13) is a tilomisole-based benzimidazothiazole derivative. Anti-inflammatory agent 8 expresses activity on COX-2 enzyme more than COX-1 with an IC_{50} of 0.09 nM. Anti-inflammatory agent 8 is orally active.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Anti-inflammatory agent 9

Cat. No.: HY-115921

Anti-inflammatory agent 9 (compound 28) is a tilomisole-based benzimidazothiazole derivative. Anti-inflammatory agent 9 expresses activity on COX-2 enzyme more than COX-1. Anti-inflammatory agent 9 is orally active.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Apyramide

Cat. No.: HY-U00046

Apyramide is an **anti-inflammatory agent (NSAID)** and behaves as a prodrug of indomethacin (HY-14397). Indomethacin is a potent, blood-brain permeable and nonselective inhibitor of COX1 and COX2.



Purity: 99.06%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Asaraldehyde (Asaronaldehyde; Asaraldehyde; 2,4,5-trimethoxy-Benzaldehyde)

Cat. No.: HY-100580

Asarylaldehyde (Asaronaldehyde), a **COX-2** inhibitor, significantly inhibits cyclooxygenase II (COX-2) activity with an IC_{50} value of 100 μg/mL.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 100 mg

Aspirin
(Acetylsalicylic Acid; ASA) Cat. No.: HY-14654

Aspirin is a non-selective and irreversible inhibitor of **COX-1** and **COX-2** with IC_{50}s of 5 and 210 μg/mL.



Purity: 99.92%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Aspirin-d3
(Acetylsalicylic Acid-d3; ASA-d3) Cat. No.: HY-14654S

Aspirin-d3 (Acetylsalicylic Acid-d3) is the deuterium labeled Aspirin. Aspirin is a non-selective and irreversible inhibitor of **COX-1** and **COX-2** with IC_{50}s of 5 and 210 μg/mL.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Aspirin-d4
(Acetylsalicylic Acid-d4; ASA-d4) Cat. No.: HY-14654S1

Aspirin-d4 (Acetylsalicylic Acid-d4) is the deuterium labeled Aspirin. Aspirin is a non-selective and irreversible inhibitor of **COX-1** and **COX-2** with IC_{50}s of 5 and 210 μg/mL.



Purity: 98.85%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Benoxaprofen
(LRCL 3794) Cat. No.: HY-13568

Benoxaprofen (LRCL 3794) is a potent and long-acting anti-inflammatory and antipyretic compound.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Benzoylgomisin O
Cat. No.: HY-N2266

Benzoylgomisin O isolated from Schisandra rubriflora, has inhibitory activity against **15-LOX**, **COX-1** and **COX-2** enzymes and anti-inflammatory activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bromfenac sodium
Cat. No.: HY-B1888A

Bromfenac sodium is a potent and orally active inhibitor of **COX**, with IC_{50}s of 5.56 and 7.45 nM for **COX-1** and **COX-2**, respectively.



Purity: >98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Bromfenac sodium hydrate
(Bromfenac monosodium salt sesquihydrate) Cat. No.: HY-B1888B

Bromfenac sodium hydrate (Bromfenac monosodium salt sesquihydrate) is a potent and orally active inhibitor of **COX**, with IC_{50}s of 5.56 and 7.45 nM for **COX-1** and **COX-2**, respectively.



Purity: 99.91%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Bromfenac-d4 sodium
Cat. No.: HY-B1888AS

Bromfenac-d4 (sodium) is deuterium labeled Bromfenac (sodium). Bromfenac sodium is a potent and orally active inhibitor of COX, with IC50s of 5.56 and 7.45 nM for COX-1 and COX-2, respectively.



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Buddlejasaponin IV
Cat. No.: HY-125131

Buddlejasaponin IV (BSIV) exerts anti-inflammatory and cytotoxic effects against cancer cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Byakangelicol
Cat. No.: HY-N0074

Byakangelicol, isolated from Angelica dahurica, inhibits interleukin-1beta (IL-1beta) -induced prostaglandin E2 (PGE2) release in A549 cells mediated by suppression of **cyclooxygenase-2 (COX-2)** expression and the activity of COX-2 enzyme.



Purity: 99.51%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

C2 Ceramide (d14:1/2:0)

Cat. No.: HY-116877

C2 Ceramide (d14:1/2:0) is a composition for diagnosing diseases associated with cyclooxygenase 2 (COX2) overexpression. C2 Ceramide (d14:1/2:0) exhibits a strong binding activity to COX2 protein (extracted from patent WO2019235824A1).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cafestol

Cat. No.: HY-N6257

Cafestol, one of the major components of coffee, is a coffee-specific diterpene from. Cafestol is a **ERK** inhibitor for AP-1-targeted activity against **PGE_2** production and the mRNA expression of **cyclooxygenase (COX)-2** in LPS-activated RAW264.7 cells.



Purity: 99.91%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Carprofen

Cat. No.: HY-B1227

Carprofen is a nonsteroid anti-inflammatory agent, acts as a multi-target **FAAH/COX** inhibitor, with **IC_{50}**s of 3.9 μM, 22.3 μM and 78.6 μM for COX-2, COX-1 and FAAH, respectively.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Carprofen-d3

Cat. No.: HY-B1227S

Carprofen-d3 is the deuterium labeled Carprofen. Carprofen is a nonsteroid anti-inflammatory agent, acts as a multi-target **FAAH/COX** inhibitor, with **IC_{50}**s of 3.9 μM, 22.3 μM and 78.6 μM for COX-2, COX-1 and FAAH, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Catechin

((+)-Catechin; Cianidanol; Catechuic acid)

Cat. No.: HY-N0898

Catechin ((+)-Catechin) inhibits cyclooxygenase-1 (**COX-1**) with an **IC_{50}** of 1.4 μM.



Purity: 98.80%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Catechin-13C3

((+)-Catechin-13C3; Cianidanol-13C3; Catechuic acid-13C3)

Cat. No.: HY-N0898S

Catechin-13C3 ((+)-Catechin-13C3) is the 13C-labeled Catechin. Catechin ((+)-Catechin) inhibits cyclooxygenase-1 (**COX-1**) with an **IC_{50}** of 1.4 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CAY10404

Cat. No.: HY-121537

CAY10404 is a potent and selective **cyclooxygenase-2 (COX-2)** inhibitor with an **IC_{50}** of 1 nM and a selectivity index (SI; COX-1 IC_{50}/COX-2 IC_{50}) of >500000.



Purity: 99.79%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Celecoxib

(SC 58635)

Cat. No.: HY-14398

Celecoxib,a selective non-steroidal anti-inflammatory drug (NSAID), is a selective **COX-2** inhibitor with an **IC_{50}** of 40 nM.



Purity: 99.59%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 1 g

Celecoxib-d3

(SC 58635-d3)

Cat. No.: HY-14398S1

Celecoxib-d3 (SC 58635-d3) is the deuterium labeled Celecoxib. Celecoxib,a selective non-steroidal anti-inflammatory drug (NSAID), is a selective **COX-2** inhibitor with an **IC_{50}** of 40 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Celecoxib-d4

Cat. No.: HY-118139S

Celecoxib-d4 is the deuterium labeled Desmethyl Celecoxib. Desmethyl Celecoxib (compound 3b) is a selective cyclooxygenase-2 (**COX-2**) inhibitor (IC_{50}=32 nM) with anti-inflammatory activities. Desmethyl Celecoxib is an analog of Celecoxib and with the optimal yield of 75%.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Celecoxib-d7

(SC 58635-d7)

Cat. No.: HY-14398S

Celecoxib-d7 (SC 58635-d7) is the deuterium labeled Celecoxib. Celecoxib,a selective non-steroidal anti-inflammatory drug (NSAID), is a selective **COX-2** inhibitor with an IC_{50} of 40 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Chebulagic acid

Cat. No.: HY-N1996

Chebulagic acid is a **COX-LOX** dual inhibitor isolated from the fruits of Terminalia chebula Retz, on angiogenesis. Chebulagic acid is a **M2 serine to asparagine 31 mutation (S31N)** inhibitor and influenza antiviral.



Purity: 99.29%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg

Chlorotrianisene

Cat. No.: HY-B2158

Chlorotrianisene is a long-acting non-steroidal estrogen and an orally active **estrogen receptor** modulator. Chlorotrianisene exhibits antiestrogenic activity. Chlorotrianisene potently inhibits the enzyme **COX-1** and inhibits platelet aggregation in whole blood.



Purity: 99.24%
Clinical Data: Launched
Size: 5 mg, 10 mg

Chlorotrianisene-d9

Cat. No.: HY-B2158S

Chlorotrianisene-d9 is the deuterium labeled Chlorotrianisene. Chlorotrianisene is a long-acting non-steroidal estrogen and an orally active **estrogen receptor** modulator. Chlorotrianisene exhibits antiestrogenic activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Choline Fenofibrate

(ABT-335)

Cat. No.: HY-14739

Choline Fenofibrate (ABT-335), a choline salt of Fenofibric acid (HY-B0760), releases free Fenofibric acid in the gastrointestinal tract. Fenofibric acid is a **PPAR** activator with antihyperlipidemic effect.



Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 100 mg

Cimicoxib

(UR-8880)

Cat. No.: HY-100516

Cimicoxib (CX) is an orally active potent and selective **COX-2** (cyclo-oxygenase-2) inhibitor. Cimicoxib exhibits promising anti-inflammatory and analgesic activity. The PK parameters of Cimicoxib in dogs given precise (2 mg/kg) and approximate doses (1.95-2.5 mg/kg) are similar.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Clematomandshurica saponin B

Cat. No.: HY-N4230

Clematomandshurica saponins B shows significant inhibitory activity on cyclooxygenase-2 (IC_{50}=2.58 mM).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Columbin

Cat. No.: HY-N0389

Columbin is an orally active diterpenoid furanolactone from Calumbae radix, has anti-inflammatory and anti-trypanosomal effects. Columbin selectively inhibits **COX-2** (EC_{50}=53.1 μM) over COX-1 (EC_{50}=327 μM).



Purity: 98.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

COX-1/2-IN-1

Cat. No.: HY-115966

COX-1/2-IN-2 is a potent **COX1/2** inhibitor. COX-1/2-IN-2 exhibits significant inhibitory effect against COX-1 and COX-2 inhibitor with IC_{50} values of 13.9±3.21μM and 6.4±0.74μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

COX-1/2-IN-2

Cat. No.: HY-115967

COX-1/2-IN-2 is a potent **COX1/2** inhibitor. COX-1/2-IN-2 exhibits significant inhibitory effect against COX-1 and COX-2 inhibitor with IC_{50} values of 9.7±0.09μM and 4.6±1.45μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

COX-2-IN-1

Cat. No.: HY-U00275

COX-2-IN-1 is potent and slective **COX-2** inhibitor with an IC_{50} of 3.9 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

COX-2-IN-10

Cat. No.: HY-115976

COX-2-IN-10 is a potent **COX-2** inhibitor. COX-2-IN-10 inhibits the production of PGE_2 in concentration dependent manner (IC_{50}=2.54 μM). COX-2-IN-10 inhibits the expression of **iNOS** and **COX-2** on mRNA and protein level . COX-2-IN-10 inhibits the production of IL-6, TNF-α and IL-1β.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

COX-2-IN-11

Cat. No.: HY-145988

COX-2-IN-11 (compound 7b2) is a potent and selective inhibitor of **COX-2**. COX-2-IN-11 has the potential for the research of inflammation diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

COX-2-IN-12

Cat. No.: HY-146370

COX-2-IN-12 (compound 3b) is a potent and selective inhibitor of **COX-2** with an IC_{50} of 19.98 μM. COX-2-IN-12 is an anti-inflammatory agent. COX-2-IN-12 shows safety in-vivo acute toxicity study.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

COX-2-IN-13

Cat. No.: HY-146371

COX-2-IN-13 (compound 13e) is a potent and selective inhibitor of **COX-2** with an IC_{50} of 0.98 μM. COX-2-IN-13 is an anti-inflammatory agent. COX-2-IN-13 shows safety in-vivo acute toxicity study.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

COX-2-IN-2

Cat. No.: HY-101655

COX-2-IN-2 is a selective and inducible **COX2** inhibitor with an IC_{50} of 0.24 μM. COX-2-IN-1 is an anti-inflammatory compound with anti-inflammatory and analgesic activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

COX-2-IN-6

Cat. No.: HY-115866

COX-2-IN-6 is a gut-restricted selective **cyclooxygenase-2 (COX-2)** inhibitor for chemoprevention of colorectal cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

COX-2-IN-7

Cat. No.: HY-115934

COX-2-IN-7 (compound 4a) is a potent, selective, and orally active inhibitor of **COX-2** with an IC_{50} of 6.585 uM. COX-2-IN-7 has higher COX-2 selectivity than Celecoxib. COX-2-IN-7 shows good in vivo anti-inflammatory and low ulcerogenic activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

COX-2-IN-8

Cat. No.: HY-115935

COX-2-IN-8 (compound 6a) is a potent, selective, and orally active inhibitor of **COX-2** with an IC_{50} of 6.585 uM. COX-2-IN-8 has higher COX-2 selectivity than Celecoxib. COX-2-IN-8 shows good in vivo anti-inflammatory and low ulcerogenic activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

COX-2-IN-9

Cat. No.: HY-115936

COX-2-IN-9 (compound 7a) is a potent, selective, and orally active inhibitor of **COX-2** with an IC_{50} of 10.17 uM. COX-2-IN-9 has higher COX-2 selectivity than Celecoxib. COX-2-IN-9 shows good in vivo anti-inflammatory and low ulcerogenic activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

COX-2/5-LOX-IN-1

Cat. No.: HY-146294

COX-2/5-LOX-IN-1 (compound 3a) is a potent and dual inhibitor of **COX-2/5-LOX**. COX-2/5-LOX-IN-1 is a benzothiophen-2-yl pyrazole carboxylic acid derivative.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

COX-2/5-LOX-IN-2

Cat. No.: HY-146295

COX-2/5-LOX-IN-2 (5b) is a potent and dual inhibitor of **COX-2/5-LOX**. COX-2/5-LOX-IN-2 is a benzothiophen-2-yl pyrazole carboxylic acid derivative.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

COX-2/sEH-IN-1

Cat. No.: HY-146704

COX-2/sEH-IN-1 (Compound 9c) is an orally active, dual **COX-2** and **sEH** (soluble epoxide hydrolase) inhibitor with IC_{50} values of 1.24 μM and 0.40 nM against COX-2 and sEH, respectively. COX-2/sEH-IN-1 shows improved anti-inflammatory activity and highly reduced cardiovascular risks.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

COX/5-LO-IN-1

(Atreleuton analog)

Cat. No.: HY-U00347

COX/5-LO-IN-1 (Atreleuton analog) is an inhibitor of **cylooxygenase** and **5-lipoxygenase (5-LO)**, used for the research of inflammatory and allergic disease states.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

COX/5-LOX-IN-1

Cat. No.: HY-146675

COX/5-LOX-IN-1 (compound 6b) is a potent and dual inhibitor of **COX/5-LOX** with IC_{50}s of 1.07, 0.55, and 0.28 μM for COX-1, COX-2, and 5-LOX enzyme, respectively. COX/5-LOX-IN-1 has the potential for the research of inflammation diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Crocin II

Cat. No.: HY-N0698

Crocin II is isolated from the fruit of Gardenia jasminoides with antioxidant, anticancer, and antidepressant activity. Crocin II inhibits NO production with an IC_{50} value of 31.1 μM. Crocin II suppresses the expressions of protein and m-RNA of **iNOS** and **COX-2**.



Purity: 99.04%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Dehydrodiisoeugenol

Cat. No.: HY-N0589

Dehydrodiisoeugenol is isolated from Myristica fragrans Houtt, shows anti-inflammatory and anti-bacterial actions. Dehydrodiisoeugenol inhibits LPS- stimulated **NF-κB** activation and cyclooxygenase (**COX**)-2 gene expression in murine macrophages.



Purity: 99.53%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Dehydroevodiamine

Cat. No.: HY-N2106

Dehydroevodiamine is a major bioactive quinazoline alkaloid isolated from Evodiae Fructus, has an antiarrhythmic effect in guinea-pig ventricular myocytes.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Deracoxib

(SC 046; SC 46; SC 59046)

Cat. No.: HY-17509

Deracoxib, a selective cyclooxygenase-2 inhibitor, is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID).



Purity: 99.77%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Desmethyl Celecoxib

Cat. No.: HY-118139

Desmethyl Celecoxib (compound 3b) is a selective cyclooxygenase-2 (**COX-2**) inhibitor (IC_{50}=32 nM) with anti-inflammatory activities. Desmethyl Celecoxib is an analog of Celecoxib and with the optimal yield of 75%.



Purity: 99.09%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

Desmethyl Celecoxib-d4

Cat. No.: HY-118139S1

Desmethyl Celecoxib-d4 is the deuterium labeled Desmethyl Celecoxib. Desmethyl Celecoxib (compound 3b) is a selective cyclooxygenase-2 (**COX-2**) inhibitor (IC_{50}=32 nM) with anti-inflammatory activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Desmethyl Naproxen-d3

Cat. No.: HY-132405S

Desmethyl Naproxen-d3 is deuterium labeled Desmethyl Naproxen. Desmethyl Naproxen is the metabolite of anti-inflammatory agent Naproxen.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Desoxo-narchinol A

Cat. No.: HY-N8435

Desoxo-narchinol A is an orally active and potent anti-inflammatory agent. Desoxo-narchinol A can be isolated from the roots and rhizomes of Nardostachys jatamansi. Desoxo-narchinol A can be used for septic shock and inflammatory diseases research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Diclofenac

Cat. No.: HY-15036

Diclofenac is a potent and nonselective anti-inflammatory agent, acts as a **COX** inhibitor, with IC_{50}s of 4 and 1.3 nM for human COX-1 and COX-2 in CHO cells, and 5.1 and 0.84 μM for ovine COX-1 and COX-2, respectively.



Purity: 99.97%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 5 g, 10 g

Diclofenac diethylamine

Cat. No.: HY-15036A

Diclofenac diethylamine is a potent and nonselective anti-inflammatory agent, acts as a **COX** inhibitor, with IC_{50}s of 4 and 1.3 nM for human COX-1 and COX-2 in CHO cells, and 5.1 and 0.84 μM for ovine COX-1 and COX-2, respectively.



Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 5 g, 10 g

Diclofenac potassium

Cat. No.: HY-15038

Diclofenac potassium is a potent and nonselective anti-inflammatory agent, acts as a **COX** inhibitor, with IC_{50}s of 4 and 1.3 nM for human COX-1 and COX-2 in CHO cells, and 5.1 and 0.84 μM for ovine COX-1 and COX-2, respectively.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 250 mg

Diclofenac Sodium

(GP 45840)

Cat. No.: HY-15037

Diclofenac Sodium (GP 45840) is a potent and nonselective anti-inflammatory agent, acts as a **COX** inhibitor, with IC_{50}s of 4 and 1.3 nM for human COX-1 and COX-2 in CHO cells, and 5.1 and 0.84 μM for ovine COX-1 and COX-2, respectively.



Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 5 g

Diclofenac-13C6 sodium heminonahydrate

Cat. No.: HY-15037S

Diclofenac-13C6 sodium heminonahydrate is the 13C-labeled Diclofenac Sodium.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Diclofenac-d4

Cat. No.: HY-15036S

Diclofenac-d4 is the deuterium labeled Diclofenac. Diclofenac is a potent and nonselective anti-inflammatory agent, acts as a **COX** inhibitor, with IC_{50}s of 4 and 1.3 nM for human COX-1 and COX-2 in CHO cells, and 5.1 and 0.84 μM for ovine COX-1 and COX-2, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Diclofenac-d4 sodium

Cat. No.: HY-15037S1

Diclofenac-d4 sodium is the deuterium labeled Diclofenac sodium.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Diflunisal

(MK-647) Cat. No.: HY-18342

Diflunisal (MK-647) is a salicylate derivative with nonsteroidal anti-inflammatory and uricosuric properties, which is used alone as an analgesic and in rheumatoid arthritis patients. The mechanism of action of diflunisal is as a Cyclooxygenase (**COX**) Inhibitor.



Purity: 99.91%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Diflunisal-d3

(MK-647-d3) Cat. No.: HY-18342S

Diflunisal-d3 (MK-647-d3) is the deuterium labeled Diflunisal. Diflunisal (MK-647) is a salicylate derivative with nonsteroidal anti-inflammatory and uricosuric properties, which is used alone as an analgesic and in rheumatoid arthritis patients.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DuP-697

Cat. No.: HY-103387

DuP-697 is a member of the vicinal diaryl heterocycles and a potent, irreversible, selective and orally active **COX-2** inhibitor (IC_{50} of 10 nM and 800 nM for human **COX-2** and **COX-1**, respectively).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Eicosatetraynoic acid

(ETYA) Cat. No.: HY-124108

Eicosatetraynoic acid (ETYA) is a nonspecific inhibitor of **cyclooxygenase** and **lipoxygenase** (ID_{50}=8 μM and 4 μM, respectively). Eicosatetraynoic acid (ETYA) activates PPARα and PPARγ chimeras at 10 μM.

Purity: ≥99.0%
Clinical Data:
Size: 1 mg

Eltenac

Cat. No.: HY-106093

Eltenac, a non-steroidal anti-inflammatory drug (NSAID), is a COX inhibitor. Eltenac shows IC50 of 0.03 μM for both COX-1 and COX-2 in isolated human whole blood.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Enflicoxib

(E 6087) Cat. No.: HY-19384

Enflicoxib (E 6087) is a nonsteroidal anti-inflammatory compound that selectively inhibits **cyclooxygenase-2** (**COX-2**). Enflicoxib does not inhibit cyclooxygenase-1 (COX-1). E-6087 shows anti-inflammatory, analgesic and antipyretic activities in animal models.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ermanin

Cat. No.: HY-N3848

Ermanin is a flavonoid isolated from Tanacetum microphyllum. Ermanin potently inhibits **iNOS**, **COX-2** activities, and inhibits platelet aggregation. Ermanin has anti-inflammatory, anti-tuberculous and anti-viral/bacterial properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Esculentoside A

Cat. No.: HY-N0632

Esculentoside A (EsA), a kind of triterpene saponin isolated from roots of Phytolacca esculenta. Esculentoside A (EsA) possesses anti-inflammatory activity in acute and chronic experimental models, has selective inhibitory activity towards cyclooxygenase-2 (**COX-2**).



Purity: 98.27%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Ethoxycoronarin D

Cat. No.: HY-N3631

Ethoxycoronarin D is a labdane diterpenes compound isolated from rhizomes. Ethoxycoronarin D selectively inhibits COX-1 with an IC_{50} of 3.8 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ethyl Caffeate

Cat. No.: HY-N6966

Ethyl Caffeate is a natural phenolic compound isolated from Bidens pilosa.



Purity: 98.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

Etodolac

(AY-24236) Cat. No.: HY-76251

Etodolac (AY-24236) is a non-steroidal anti-inflammatory compound that is a non-selective inhibitor of COX (IC_{50}=53.5 nM).



Purity: 99.11%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg

Etofenamate

Cat. No.: HY-17361

Etofenamate, a non-steroid anti-inflammatory drug (**NSAID**) and a non-selective **COX** inhibitor, possesses analgesic, anti-rheumatic, antipyretic and anti-inflammatory properties. Etofenamate is used in the research for osteoarthritis, arthritis and other inflammatory diseases.



Purity: 98.14%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Etofenamate-d4

Cat. No.: HY-17361S

Etofenamate-d4 is the deuterium labeled Etofenamate. Etofenamate, a non-steroid anti-inflammatory drug (**NSAID**) and a non-selective **COX** inhibitor, possesses analgesic, anti-rheumatic, antipyretic and anti-inflammatory properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Etoricoxib

(MK-0663; L-791456) Cat. No.: HY-15321

Etoricoxib (MK-0663) is a non steroidal anti-inflammatory agent, acting as a selective and orally active **COX-2** inhibitor, with IC_{50}s of 1.1 μM and 116 μM for COX-2 and COX-1 in human whole blood.



Purity: 99.10%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Etoricoxib-13C,d3

(MK-0663-13C,d3; L-791456-13C,d3) Cat. No.: HY-15321S1

Etoricoxib-13C,d3 is the 13C- and deuterium labeled. Etoricoxib (MK-0663) is a non steroidal anti-inflammatory agent, acting as a selective and orally active COX-2 inhibitor, with IC50s of 1.1 μM and 116 μM for COX-2 and COX-1 in human whole blood.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Etoricoxib-d4

(MK-0663-d4; L-791456-d4) Cat. No.: HY-15321S

Etoricoxib D4 (MK-0663 D4) is a deuterium labeled Etoricoxib. Etoricoxib is a non steroidal anti-inflammatory agent, acting as a selective and orally active **COX-2** inhibitor, with IC_{50}s of 1.1 μM and 116 μM for COX-2 and COX-1 in human whole blood.



Purity: 99.35%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

EXP3179

(Losartan Carboxaldehyde; DuP 167) Cat. No.: HY-114950

EXP3179 is an important intermediate aldehyde metabolite of Losartan. EXP3179 has no AT1-R–blocking activity, but potently inhibits the expression of endothelial cyclooxygenase (COX)-2. EXP3179 exerts potent anti-inflammatory actions.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Fenbufen

(CL-82204) Cat. No.: HY-B1138

Fenbufen (CL-82204) is an orally active **non-steroidal anti-inflammatory drug (NSAID)**, with analgetic and antipyretic effects. Fenbufen has potent activity in a variety of animal model, including carageenin edema, UV erythema and adjuvant arthritis.



Purity: 98.99%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Fenbufen-d9

Cat. No.: HY-B1138S

Fenbufen-d9 (CL-82204-d9) is the deuterium labeled Fenbufen. Fenbufen (CL-82204) is an orally active **non-steroidal anti-inflammatory drug (NSAID)**, with antipyretic effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Fenofibric acid

(FNF acid) Cat. No.: HY-B0760

Fenofibric acid, an active metabolite of fenofibrate, is a **PPAR** activitor, with EC_{50}s of 22.4 μM, 1.47 μM, and 1.06 μM for PPARα, PPARγ and PPARδ, respectively; Fenofibric acid also inhibits **COX-2** enzyme activity, with an IC_{50} of 48 nM.



Purity: 99.67%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Fenofibric acid-d6

Cat. No.: HY-B0760S

Fenofibric acid-d6 (FNF acid-d6) is the deuterium labeled Fenofibric acid.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Fenoprofen Calcium

Cat. No.: HY-B0288A

Fenoprofen Calcium is a nonsteroidal, anti-inflammatory antiarthritic agent.



Purity: >98%
Clinical Data: Launched
Size: 500 mg

Fenoprofen Calcium hydrate

(Fenoprofen calcium salt dihydrate)

Cat. No.: HY-B0288B

Fenoprofen Calcium hydrate is a nonsteroidal, anti-inflammatory antiarthritic agent.



Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Firocoxib

(ML 1785713)

Cat. No.: HY-14670

Firocoxib (ML 1785713) is a potent, selective and orally active **COX-2** inhibitor with an IC_{50} of 0.13 μM. Firocoxib shows 58-fold more selective for **COX-2** than COX-1 (IC_{50} of 7.5 μM). Firocoxib has anti-inflammatory effects.



Purity: 98.42%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Firocoxib-d4

Cat. No.: HY-14670S

Firocoxib-d4 (ML 1785713-d4) is the deuterium labeled Firocoxib. Firocoxib (ML 1785713) is a potent, selective and orally active **COX-2** inhibitor with an IC_{50} of 0.13 μM. Firocoxib shows 58-fold more selective for **COX-2** than COX-1 (IC_{50} of 7.5 μM).



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

FK 3311

(COX-2 Inhibitor V)

Cat. No.: HY-14445

FK 3311 (COX-2 Inhibitor V) is a selective inhibitor of **COX-2** with antiinflammatory agent.



Purity: 98.38%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

Floctafenine

Cat. No.: HY-A0259

Floctafenine, a nonsteroidal anti-inflammatory agent (NSAID), acts as an effective analgesic agent. Floctafenine is an inhibitor of **COX-1 and COX-2 activities in vitro,showing a slightly higher potency towards COX-I. Floctafenine is used for the research of short term pain treatment.**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Flosulide

(ZK 38997; CGP 28238)

Cat. No.: HY-U00083

Flosulide is a potent and selective **COX-2** inhibitor, used for the treatment for inflammatory diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Flufenamic acid

Cat. No.: HY-B1221

Flufenamic acid is a non-steroidal anti-inflammatory agent, inhibits cyclooxygenase (**COX**), activates **AMPK**, and also modulates ion channels, blocking **chloride channels** and **L-type Ca^{2+} channels**, modulating non-selective cation channels (**NSC**), activating...



Purity: 99.85%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Flufenamic acid-d4

Cat. No.: HY-B1221S

Flufenamic acid-d4 is deuterium labeled Flufenamic acid.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Flunixin meglumine

Cat. No.: HY-B0386

Flunixin Meglumine is a potent inhibitor of COX used as analgesic agent with anti-inflammatory and antipyretic activity. Target: COX Flunixin meglumine is a potent, non-narcotic, non-steroidal analgesic agent with anti-inflammatory and antipyretic activity.



Purity: 99.65%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Flunixin-d3

Cat. No.: HY-121046S

Flunixin-d3 is the deuterium labeled Flunixin. Flunixin Meglumine is a potent inhibitor of COX used as analgesic agent with anti-inflammatory and antipyretic activity.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Flurbiprofen

(dl-Flurbiprofen)

Cat. No.: HY-10582

Flurbiprofen (dl-Flurbiprofen) is a potent, orally active nonsteroidal anti-inflammatory agent (NSAIA/NSAID), with antipyretic and analgesic activities.



Purity: 99.92%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Flurbiprofen axetil

Cat. No.: HY-101481

Flurbiprofen axetil is a non-selective **cyclooxygenase (COX)** inhibitor. Flurbiprofen axetil has anti-inflammatory effect.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Flurbiprofen-13C,d3

(dl-Flurbiprofen-13C,d3)

Cat. No.: HY-10582S2

Flurbiprofen-13C,d3 is the 13C- and deuterium labeled. Flurbiprofen (dl-Flurbiprofen) is a potent, orally active nonsteroidal anti-inflammatory agent (NSAIA/NSAID), with antipyretic and analgesic activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Flurbiprofen-d3

(dl-Flurbiprofen-d3)

Cat. No.: HY-10582S

Flurbiprofen-d3 (dl-Flurbiprofen-d3) is the deuterium labeled Flurbiprofen. Flurbiprofen (dl-Flurbiprofen) is a potent, orally active nonsteroidal anti-inflammatory agent (NSAIA/NSAID), with antipyretic and analgesic activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 50 mg

Flurbiprofen-d5

(dl-Flurbiprofen-d5)

Cat. No.: HY-10582S1

Flurbiprofen-d5 (dl-Flurbiprofen-d5) is the deuterium labeled Flurbiprofen. Flurbiprofen (dl-Flurbiprofen) is a potent, orally active nonsteroidal anti-inflammatory agent (NSAIA/NSAID), with antipyretic and analgesic activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 50 mg

FPL 62064

Cat. No.: HY-105024

FPL 62064 is a potent **5-lipoxygenase (5-LOX)** and **COX** dual inhibitor, with IC_{50} values of 3.5 μM and 3.1 μM for RBL-1 cytosolic 5-lipoxygenase and prostaglandin synthetase (cyclooxygenase), respectively. FPL 62064 has potent anti-inflammatory activity.



Purity: 98.46%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

FR-188582

Cat. No.: HY-U00146

FR-188582 is a highly selective inhibitor of **cyclooxygenase** (**COX**)-2, with an IC_{50} value of 17 nM.



Purity: 99.21%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg

FR122047

Cat. No.: HY-103386

FR122047 (hydrochloride) is a selective and oral active inhibitor of **COX-1** with an IC_{50} of 28 nM. FR122047 hydrochloride has antiplatelet, analgesic and anti-inflammatory effects in vivo.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Gallic acid

(3,4,5-Trihydroxybenzoic acid)

Cat. No.: HY-N0523

Gallic acid (3,4,5-Trihydroxybenzoic acid) is a natural polyhydroxyphenolic compound and an free radical scavenger to inhibit **cyclooxygenase-2 (COX-2)**. Gallic acid has various activities, such as antimicrobial, antioxidant, antimicrobial, anti-inflammatory, and anticance activities.



Purity: 99.85%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Gallic acid hydrate

(3,4,5-Trihydroxybenzoic acid hydrate)

Cat. No.: HY-N0523A

Gallic acid (3,4,5-Trihydroxybenzoic acid) hydrate is a natural polyhydroxyphenolic compound and an free radical scavenger to inhibit **cyclooxygenase-2 (COX-2)**.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Ginsenoside C-K

(Ginsenoside compound K; Ginsenoside K)

Cat. No.: HY-N0904

Ginsenoside C-K, a bacterial metabolite of G-Rb1, exhibits anti-inflammatory effects by reducing **iNOS** and **COX-2**. Ginsenoside C-K exhibits an inhibition against the activity of **CYP2C9** and **CYP2A6** in human liver microsomes with IC_{50}s of 32.0±3.6 μM and 63.6±4.2 μM, respectively.



Purity: 98.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Ginsenoside Rb3

(Gypenoside IV)

Cat. No.: HY-N0041

Ginsenoside Rb3 is extracted from steamed Panax notoginseng. Ginsenoside Rb3 exhibits inhibitory effect on TNFα-induced **NF-κB** transcriptional activity with an IC_{50} of 8.2 μM in 293T cell lines. Ginsenoside Rb3 also inhibits the induction of **COX-2** and **iNOS** mRNA.



Purity: 99.12%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Ginsenoside Rd

(Gypenoside VIII)

Cat. No.: HY-N0043

Ginsenoside Rd inhibits TNFα-induced **NF-κB** transcriptional activity with an IC_{50} of 12.05±0.82 μM in HepG2 cells. Ginsenoside Rd inhibits expression of **COX-2** and **iNOS** mRNA. Ginsenoside Rd also inhibits Ca^{2+} influx.



Purity: 98.02%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Ginsenoside Rg5

Cat. No.: HY-N0908

Ginsenoside Rg5 is the main component of Red ginseng. Ginsenoside blocks binding of **IGF-1** to its receptor with an IC_{50} of ~90 nM. Ginsenoside Rg5 also inhibits the mRNA expression of **COX-2** via suppression of the DNA binding activities of **NF-κB p65**.



Purity: 99.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Gnetol

Cat. No.: HY-126052

Gnetol is a phenolic compound isolated from the root of Gnetum ula Brongn. Gnetol potently inhibits **COX-1** (IC_{50} of 0.78 μM) and **HDAC**. Gnetol is a potent **tyrosinase** inhibitor with an IC_{50} of 4.5 μM for murine tyrosinase and suppresses melanin biosynthesis.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg

Guaiacol

(2-Methoxyphenol)

Cat. No.: HY-N1380

Guaiacol, a phenolic compound, inhibits LPS-stimulated **COX-2** expression and **NF-κB** activation. Anti-inflammatory activity.



Purity: 99.70%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg

Guaiacol-d3

(2-Methoxyphenol-d3)

Cat. No.: HY-N1380S1

Guaiacol-d3 (2-Methoxyphenol-d3) is the deuterium labeled Guaiacol. Guaiacol, a phenolic compound, inhibits LPS-stimulated COX-2 expression and NF-κB activation. Guaiacol has an anti-inflammatory activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GW-406381

Cat. No.: HY-119304

GW406381, a highly selective **cyclooxygenase-2 (COX-2)** inhibitor, attenuates spontaneous ectopic discharge in sural nerves of rats following chronic constriction injury.



Purity: 99.69%
Clinical Data:
Size: 10 mM × 1 mL, 1 mg

Hamaudol

Cat. No.: HY-N6891

Hamaudol is a chromone isolated from Saposhnikovia divaricata. Hamaudol shows significant inhibitory activity on **cyclooxygenase (COX)-1** and **COX-2** activities with IC_{50} values of 0.30, 0.57 mM, respectively, and has potent analgesia and anti-inflammary effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Harpagoside

Cat. No.: HY-N0396

Harpagoside is isolated from Harpagophytum procumbens (Hp). Harpagoside has inhibitory effects on **COX-1** and **COX-2** activity and inhibits NO production.



Purity: 98.35%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Hexahydrocurcumin

Cat. No.: HY-N0929

Hexahydrocurcumin is one of the major metabolites of curcumin and a selective, orally active **COX-2** inhibitor. Hexahydrocurcumin is inactive against COX-1. Hexahydrocurcumin has antioxidant, anticancer and anti-inflammatory activities.



Purity: 99.70%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

Humulone

(α-Lupulic acid)

Cat. No.: HY-N6084

Humulone (α-Lupulic acid), a prenylated phloroglucinol derivative, is a potent **cyclooxygenase-2 (COX-2)** inhibitor. Humulone acts as a positive modulator of **$GABA_A$ receptor** at low micromolar concentrations. Humulone is an inhibitor of bone resorption.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Ibufenac

(Dytransin)

Cat. No.: HY-W040672

Ibufenac (Dytransin) is an analog of Ibuprofen. Ibuprofen is a non-steroidal anti-rheumatoid agen and non-selective COX inhibitor used to treat mild-moderate pain, fever, and inflammation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ibuprofen

((±)-Ibuprofen)

Cat. No.: HY-78131

Ibuprofen is an anti-inflammatory agent targeting **COX-1** and **COX-2** with IC_{50}s of 13 μM and 370 μM, respectively.



Purity: 99.97%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Ibuprofen impurity 1

Cat. No.: HY-131258

Ibuprofen impurity 1 is an Ibuprofen impurity. Ibuprofen is an anti-inflammatory inhibitor targeting **COX-1** and **COX-2** with IC_{50}s of 13 μM and 370 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

Ibuprofen Impurity F

Cat. No.: HY-131259

Ibuprofen Impurity F is an Ibuprofen impurity. Ibuprofen is an anti-inflammatory inhibitor targeting **COX-1** and **COX-2** with IC_{50}s of 13 μM and 370 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ibuprofen Impurity K

Cat. No.: HY-131260

Ibuprofen Impurity K is an Ibuprofen impurity. Ibuprofen is an anti-inflammatory inhibitor targeting **COX-1** and **COX-2** with IC_{50}s of 13 μM and 370 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ibuprofen-13C,d3

((±)-Ibuprofen-13C,d3)

Cat. No.: HY-78131S1

Ibuprofen-13C,d3 is the 13C- and deuterium labeled. Ibuprofen is an anti-inflammatory agent targeting COX-1 and COX-2 with IC50s of 13 μM and 370 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ibuprofen-d3

((±)-Ibuprofen-d3) Cat. No.: HY-78131S

Ibuprofen D3 is a deuterium labeled Ibuprofen. Ibuprofen is a COX-1 and COX-2 inhibitor with IC_{50}s of 13 μM and 370 μM.



Purity: 99.15%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg

Iguratimod

(T614) Cat. No.: HY-17009

Iguratimod is an antirheumatic agent, acts as an inhibitor of **COX-2**, with an IC_{50} of 20 μM (7.7 μg/mL), but shows no effect on COX-1. Iguratimod also inhibits macrophage migration inhibitory factor (**MIF**) with an IC_{50} of 6.81 μM.



Purity: 99.97%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Iguratimod-d5

(T614-d5) Cat. No.: HY-17009S

Iguratimod-d5 (T614-d5) is the deuterium labeled Iguratimod. Iguratimod is an antirheumatic agent, acts as an inhibitor of **COX-2**, with an IC_{50} of 20 μM (7.7 μg/mL), but shows no effect on COX-1.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Imrecoxib

(BAP-909) Cat. No.: HY-114200

Imrecoxib (BAP-909) is a novel and selective cyclooxygenase 2 (**COX-2**) inhibitor with an IC_{50} value of 18 nM, it also inhibits COX1- activity with an IC_{50} value of 115 nM. Imrecoxib (BAP-909) has anti-inflammatory effect.



Purity: 99.38%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg

Indobufen

(Ibustrin) Cat. No.: HY-18763

Indobufen is a platelet aggregation inhibitor. Indobufen is a reversible platelet cyclooxygenase (**Cox**) activity inhibitor. Indobufen suppresses thromboxane A_2 (TxA_2) synthesis. Indobufen down-regulates tissue factor (TF) in monocytes.



Purity: 99.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg

Indobufen-d5

(Ibustrin-d5) Cat. No.: HY-18763S

Indobufen-d5 is deuterium labeled Indobufen. Indobufen is a platelet aggregation inhibitor. Indobufen is a reversible platelet cyclooxygenase (Cox) activity inhibitor. Indobufen suppresses thromboxane A2 (TxA2) synthesis. Indobufen down-regulates tissue factor (TF) in monocytes.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Indomethacin

(Indometacin) Cat. No.: HY-14397

Indomethacin (Indometacin) is a potent, blood-brain permeable and nonselective inhibitor of **COX1** and **COX2**, with IC_{50}s of 18 nM and 26 nM for human COX-1 and COX-2, respectively, in CHO cells. Indomethacin disrupts **autophagic flux** by disturbing the normal functioning of lysosomes.



Purity: 99.97%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Indomethacin farnesil

(Indometacin farnesil) Cat. No.: HY-111274

Indomethacin farnesil is an orally active prodrug of Indomethacin. Indomethacin (Indometacin) is a potent, blood-brain permeable and nonselective inhibitor of **COX1** and **COX2**, with IC_{50}**s** of 18 nM and 26 nM for human COX-1 and COX-2, respectively, in CHO cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Indomethacin sodium hydrate

(Indometacin sodium hydrate) Cat. No.: HY-14397A

Indomethacin sodium hydrate (Indometacin sodium hydrate) is a potent, blood-brain permeable and nonselective inhibitor of **COX1** and **COX2**, with IC_{50}s of 18 nM and 26 nM for human COX-1 and COX-2, respectively, in CHO cells.



Purity: 96.84%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g

Indomethacin-d4

(Indometacin-d4) Cat. No.: HY-14397S

Indomethacin-D4 (Indometacin-D4) is a deuterium labeled Indomethacin. Indomethacin is a potent, blood-brain permeable and nonselective inhibitor of **COX1** and **COX2**, with IC_{50}s of 18 nM and 26 nM for human COX-1 and COX-2, respectively, in CHO cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Indomethacin-d4 Methyl Ester

Cat. No.: HY-14397S1

Indomethacin-d4 Methyl Ester is the deuterium labeled Indomethacin. Indomethacin (Indometacin) is a potent, blood-brain permeable and nonselective inhibitor of **COX1** and **COX2**, with IC_{50}s of 18 nM and 26 nM for human COX-1 and COX-2, respectively, in CHO cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Inulicin

(1-O-Acetylbritannilactone)

Cat. No.: HY-N0896

Inulicin (1-O-Acetylbritannilactone) is an active compound that inhibits VEGF-mediated activation of **Src** and **FAK**. Inulicin (1-O-Acetylbritannilactone) inhibits LPS-induced PGE_2 production and **COX-2** expression, and **NF-κB** activation and translocation.



Purity: 99.42%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Isofraxidin

Cat. No.: HY-N0774

Isofraxidin, a coumarin component from Acanthopanax senticosus, inhibits **MMP-7** expression and cell invasion of human hepatoma cells. Isofraxidin inhibits the phosphorylation of **ERK1/2** in hepatoma cells.



Purity: 98.14%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Isoorientin

(Homoorientin)

Cat. No.: HY-N0767

Isoorientin is a potent inhibitor of **COX-2** with an IC_{50} value of 39 μM.



Purity: 99.26%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

Isoxicam

Cat. No.: HY-B1130

Isoxicam is an orally active, long-acting, non-steroidal anti-inflammatory agent for the research of arthritis. Isoxicam is a nonselective inhibitor of **COX-1** and **COX-2**.



Purity: 99.11%
Clinical Data: Launched
Size: 100 mg, 250 mg

Jaceosidin

Cat. No.: HY-N0831

Jaceosidin is a flavonoid isolated from Artemisia vestita, induces apoptosis in cancer cells, activates **Bax** and down-regulates Mcl-1 and c-FLIP expression.



Purity: 99.51%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg

Ketoprofen

(RP-19583)

Cat. No.: HY-B0227

Ketoprofen (RP-19583) is a non-steroidal antiinflammatory agent, acting as a potent inhibitor of **COX**, with IC_{50}s of 2 nM and 26 nM for COX-1 and COX-2 in human blood monocytes, respectively.



Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Ketoprofen-13C,d3

(RP-19583-13C,d3)

Cat. No.: HY-B0227S2

Ketoprofen-13C,d3 is the 13C- and deuterium labeled. Ketoprofen (RP-19583) is a non-steroidal antiinflammatory agent, acting as a potent inhibitor of COX, with IC50s of 2 nM and 26 nM for COX-1 and COX-2 in human blood monocytes, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ketoprofen-d3

(RP-19583-d3)

Cat. No.: HY-B0227S

Ketoprofen-d3 (RP-19583-d3) is the deuterium labeled Ketoprofen. Ketoprofen (RP-19583) is a non-steroidal antiinflammatory agent, acting as a potent inhibitor of **COX**, with IC_{50}s of 2 nM and 26 nM for COX-1 and COX-2 in human blood monocytes, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ketoprofen-d4

(RP-19583-d4)

Cat. No.: HY-B0227S1

Ketoprofen-d4 (RP-19583-d4) is the deuterium labeled Ketoprofen. Ketoprofen (RP-19583) is a non-steroidal antiinflammatory agent, acting as a potent inhibitor of **COX**, with IC_{50}s of 2 nM and 26 nM for COX-1 and COX-2 in human blood monocytes, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ketorolac
(RS37619) Cat. No.: HY-B0580

Ketorolac is a non-steroidal anti-inflammatory agent, acting as a nonselective **COX** inhibitor, with **IC_{50}**s of 20 nM for COX-1 and 120 nM for COX-2.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Ketorolac D4
Cat. No.: HY-B0580S1

Ketorolac D4 (RS37619 D4) is the deuterium labeled Ketorolac. Ketorolac is a non-steroidal anti-inflammatory agent, acting as a nonselective **COX** inhibitor, with **IC_{50}**s of 20 nM for COX-1 and 120 nM for COX-2.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ketorolac tromethamine salt (Ketorolac Tromethamine; Ketorolac tris salt; RS37619 tromethamine salt)
Cat. No.: HY-B0138

Ketorolac tromethamine salt (RS37619 tromethamine salt) is a non-steroidal anti-inflammatory agent, acting as a nonselective **COX** inhibitor, with **IC_{50}**s of 20 nM for COX-1 and 120 nM for COX-2.



Purity: 99.94%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Ketorolac-d5
Cat. No.: HY-B0580S

Ketorolac D5 is a deuterium labeled Ketorolac. Ketorolac is a non-steroidal anti-inflammatory agent, acting as a nonselective **COX** inhibitor, with **IC_{50}**s of 20 nM for COX-1 and 120 nM for COX-2.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Licarin A
((+)-Licarin A) Cat. No.: HY-N2252

Licarin A ((+)-Licarin A), a neolignan, significantly and dose-dependently reduces TNF-α production (IC_{50}=12.6 μM) in dinitrophenyl-human serum albumin (DNP-HSA)-stimulated RBL-2H3 cells. Anti-allergic effects. Licarin A reduces **TNF-α** and **PGD2** production, and **COX-2** expression.



Purity: 98.16%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Licofelone
(ML-3000) Cat. No.: HY-B1452

Licofelone (ML-3000) is a dual **COX/5-lipoxygenase (5-LOX)** inhibitor (**IC_{50}**=0.21/0.18 μM, respectively) for the treatment of osteoarthritis. Licofelone exerts anti-inflammatory and anti-proliferative effects.



Purity: 98.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Licofelone-d4
Cat. No.: HY-B1452S

Licofelone-d4 (ML-3000-d4) is the deuterium labeled Licofelone. Licofelone (ML-3000) is a dual **COX/5-lipoxygenase (5-LOX)** inhibitor (**IC_{50}**=0.21/0.18 μM, respectively) for the treatment of osteoarthritis.



Purity: >98%
Clinical Data:
Size: 5 mg

Lornoxicam
(Chlortenoxicam; Ro 13-9297) Cat. No.: HY-B0367

Lornoxicam (Chlortenoxicam), a COX-1 and COX-2 inhibitor, is a new nonsteroidal anti-inflammatory drug (NSAID). Target: COX Lornoxicam showed a balanced inhibition of COX-1/-2 exhibiting the lowest IC50 (0.005 microM/0.008 microM) of the large panel of NSAIDs tested.



Purity: 99.84%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

Lornoxicam-d4
(Chlortenoxicam-d4; Ro 13-9297-d4) Cat. No.: HY-B0367S

Lornoxicam-d4 (Chlortenoxicam-d4) is the deuterium labeled Lornoxicam. Lornoxicam (Chlortenoxicam), a COX-1 and COX-2 inhibitor, is a new nonsteroidal anti-inflammatory drug (NSAID).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 50 mg

Loxoprofen
Cat. No.: HY-B0578

Loxoprofen is a non-steroidal anti-inflammatory agent with analgesic and anti-pyretic properties. Loxoprofen sodium is a nonselective **COX** inhibitor with **IC_{50}**s of 6.5 and 13.5 μM for COX-1 and COX-2, respectively.



Purity: 99.76%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Loxoprofen sodium

Cat. No.: HY-B0578A

Loxoprofen sodium is a non-steroidal anti-inflammatory agent with analgesic and anti-pyretic properties. Loxoprofen sodium is a nonselective **COX** inhibitor with **IC_{50}**s of 6.5 and 13.5 μM for COX-1 and COX-2, respectively.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg

Loxoprofen-d4

Cat. No.: HY-B0578S

Loxoprofen-d4 is deuterium labeled Loxoprofen. Loxoprofen is a non-steroidal anti-inflammatory agent with analgesic and anti-pyretic properties. Loxoprofen sodium is a nonselective COX inhibitor with IC50s of 6.5 and 13.5 μM for COX-1 and COX-2, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lumiracoxib

(COX-189)

Cat. No.: HY-13507

Lumiracoxib is a potent,selective and orally active **COX-2** inhibitor with a K_i value of 0.06μM. Lumiracoxib acts as a nonselective **NSAID** with anti-inflammatory, analgesic and antipyretic activities. Lumiracoxib can be used for osteoarthritis and bone cancer research.



Purity: 99.65%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg

Lumiracoxib-d6

Cat. No.: HY-13507S

Lumiracoxib-d6 (COX-189-d6) is the deuterium labeled Lumiracoxib. Lumiracoxib is a potent,selective and orally active **COX-2** inhibitor with a K_i value of 0.06μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

LY 178002

Cat. No.: HY-101579

LY 178002 is a potent inhibitor of **5-lipoxygenase (5-LPO)**, **phospholipase A2**, with **IC_{50}** of 0.6 μM for 5-lipoxygenase, inhibits cellular production of LTB4 by human polymorphonuclear leukocytes, and shows relatively weak inhibition on **cyclooxygenase**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Macelignan

((+)-Anwulignan; Anwuligan)

Cat. No.: HY-N0064

Macelignan ((+)-Anwulignan; Anwuligan) is an orally active **lignan** isolated from Myristica fragrans. Macelignan possesses many pharmacological activities, including anti-inflammatory, anti-cancer, anti-diabetes, and neuroprotective activities.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Madecassic acid

Cat. No.: HY-N0569

Madecassic acid is isolated from Centella asiatica (Umbelliferae). Madecassic acid has anti-inflammatory properties caused by **iNOS**, **COX-2**, **TNF-alpha**, **IL-1beta**, and **IL-6** inhibition via the downregulation of **NF-κB** activation in RAW 264.7 macrophage cells.



Purity: 98.34%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Mavacoxib

Cat. No.: HY-119447

Mavacoxib is a selective, oral long-acting **cyclooxygenase-2 (COX-2)** inhibitor and a long-acting non-steroidal anti-inflammatory drug (NSAID). Mavacoxib is used to treat pain and inflammation associated with degenerative joint disease in dogs.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Mavacoxib-d4

Cat. No.: HY-119447S

Mavacoxib-d4 is the deuterium labeled Mavacoxib. Mavacoxib is a selective, oral long-acting **cyclooxygenase-2 (COX-2)** inhibitor and a long-acting non-steroidal anti-inflammatory drug (NSAID).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mefenamic acid

Cat. No.: HY-B0574

Mefenamic acid is a non-steroidal anti-inflammatory agent, acting as a competitive inhibitor of **hCOX-1** and **hCOX-2**, with **IC_{50}**s of 40 nM and 3 μM for hCOX-1 and hCOX-2, respectively.



Purity: 99.97%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 5 g, 10 g

Mefenamic acid D4

Cat. No.: HY-B0574S

Mefenamic acid D4 is a deuterium labeled Mefenamic acid. Mefenamic acid is a non-steroidal anti-inflammatory agent, acting as a competitive inhibitor of **hCOX-1** and **hCOX-2**, with IC_{50}s of 40 nM and 3 μM for hCOX-1 and hCOX-2, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mefenamic acid-13C6

Cat. No.: HY-B0574S2

Mefenamic acid-13C6 is the 13C-labeled Mefenamic acid. Mefenamic acid is a non-steroidal anti-inflammatory agent, acting as a competitive inhibitor of **hCOX-1** and **hCOX-2**, with IC_{50}s of 40 nM and 3 μM for hCOX-1 and hCOX-2, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mefenamic Acid-d3

Cat. No.: HY-B0574S1

Mefenamic Acid-d3 is the deuterium labeled Mefenamic acid. Mefenamic acid is a non-steroidal anti-inflammatory agent, acting as a competitive inhibitor of **hCOX-1** and **hCOX-2**, with IC_{50}s of 40 nM and 3 μM for hCOX-1 and hCOX-2, respectively.



Purity: >98%
Clinical Data:
Size: 2.5 mg, 25 mg

Meloxicam

Cat. No.: HY-B0261

Meloxicam is a non-steroidal antiinflammatory agent, inhibits **COX** activity, with IC_{50}s of 0.49 μM and 36.6 μM for COX-2 and COX-1, respectively.



Purity: 99.88%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Meloxicam-13C,d3

Cat. No.: HY-B0261S2

Meloxicam-13C,d3 is deuterium labeled Meloxicam. Meloxicam is a non-steroidal antiinflammatory agent, inhibits COX activity, with IC50s of 0.49 μM and 36.6 μM for COX-2 and COX-1, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Meloxicam-d3

Cat. No.: HY-B0261S

Meloxicam-d3 is deuterium labeled Meloxicam. Meloxicam is a non-steroidal antiinflammatory agent, inhibits COX activity, with IC_{50}s of 0.49 μM and 36.6 μM for COX-2 and COX-1, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Meloxicam-d3-1

Cat. No.: HY-B0261S1

Meloxicam-d3-1 is the deuterium labeled Meloxicam. Meloxicam is a non-steroidal antiinflammatory agent, inhibits **COX** activity, with IC_{50}s of 0.49 μM and 36.6 μM for COX-2 and COX-1, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Metamizole sodium

Cat. No.: HY-B1279A

Metamizole sodium is a non-opioid compound with excellent analgesic and antipyretic effects. Metamizole (sodium) is a **cyclooxygenase-3 (COX-3)** inhibitor.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Metamizole sodium hydrate

Cat. No.: HY-B1279

Metamizole sodium hydrate is a potent analgesic drug that has been demonstrated to inhibit cyclooxygenase (COX).



Purity: ≥98.0%
Clinical Data: Launched
Size: 500 mg

Metamizole-d3 sodium

Cat. No.: HY-B1279AS

Metamizole-d3 sodium is the deuterium labeled Metamizole sodium. Metamizole sodium is a non-opioid compound with excellent analgesic and antipyretic effects. Metamizole sodium is a **cyclooxygenase-3 (COX-3)** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Methyl Salicylate

(Wintergreen oil)

Cat. No.: HY-Y0189

Methyl Salicylate (Wintergreen oil) is a topical analgesic and anti-inflammatory agent. Also used as a pesticide, a denaturant, a fragrance ingredient, and a flavoring agent in food and tobacco products. A systemic acquired resistance (SAR) signal in tobacco.



Purity: >98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg

Metyrosine

Cat. No.: HY-W015007

Metyrosine is a selective **tyrosine hydroxylase enzyme** inhibitor. Metyrosine exerts anti-inflammatory and anti-ulcerative effects. Metyrosine significantly inhibits high COX-2 activity. Metyrosine is a very effective agent for blood pressure control.



Purity: 98.79%
Clinical Data: Launched
Size: 25 mg, 50 mg, 100 mg

Metyrosine-13C9,d7,15N

Cat. No.: HY-W015007S

Metyrosine-13C9,d7,15N is the deuterium, 13C-, and 15-labeled Metyrosine. Metyrosine is a selective **tyrosine hydroxylase enzyme** inhibitor. Metyrosine exerts anti-inflammatory and anti-ulcerative effects. Metyrosine significantly inhibits high COX-2 activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mofezolac

Cat. No.: HY-120824

Mofezolac, a non-steroidal anti-inflammatory drug (NSAID), is a selective, reversible and orally active **COX-1** inhibitor with an IC_{50} of 1.44 nM. Mofezolac shows weak inhibitory activity on COX-2 (IC_{50} of 447 nM). Mofezolac can relieve pain and has anti-inflammatory activities.



Purity: 98.83%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

N-tert-Butyl-α-phenylnitrone

Cat. No.: HY-128463

N-tert-Butyl-α-phenylnitrone is a nitrone-based free radical scavenger that forms nitroxide spin adducts. N-tert-Butyl-α-phenylnitrone inhibits **COX2** catalytic activity.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg, 250 mg, 500 mg

N-trans-Feruloyltyramine

(N-feruloyltyramine; Moupinamide)

Cat. No.: HY-N2410

N-trans-Feruloyltyramine (N-feruloyltyramine), an alkaloid from Piper nigru, is an inhibitor of **COX1** and **COX2**, with potential antioxidant properties. N-trans-Feruloyltyramine possesses anti-inflammatory activity.



Purity: 98.64%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Nabumetone

(BRL14777)

Cat. No.: HY-B0559

Nabumetone is an orally active non-acidic anti-inflammatory agent, acts as a potent and selective **COX-2** inhibitor, and is the prodrug of the active metabolite 6MNA.



Purity: 99.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Nabumetone-d3

(BRL14777-d3)

Cat. No.: HY-B0559S

Nabumetone-d3 (BRL14777-d3) is the deuterium labeled Nabumetone. Nabumetone is an orally active non-acidic anti-inflammatory agent, acts as a potent and selective **COX-2** inhibitor, and is the prodrug of the active metabolite 6MNA.



Purity: >98%
Clinical Data: No Development Reported
Size: 2.5 mg, 1 mg, 5 mg, 10 mg

Naproxen

((S)-Naproxen)

Cat. No.: HY-15030

Naproxen is a **COX-1** and **COX-2** inhibitor with IC_{50}s of 8.72 and 5.15 μM, respectively in cell assay.



Purity: 99.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 5 g, 10 g

Naproxen etemesil

(LT-NS 001; MX 1094)

Cat. No.: HY-19675

Naproxen etemesil is a lipophilic, non-acidic, inactive prodrug of naproxen that is hydrolysed to pharmacologically active Naproxen once absorbed. Naproxen is a **COX-1** and **COX-2** inhibitor with IC_{50}s of 8.72 and 5.15 μM, respectively in cell assay.



Purity: 99.89%
Clinical Data: Phase 3
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Naproxen sodium

Cat. No.: HY-15030A

Naproxen sodium is a **COX-1** and **COX-2** inhibitor with IC_{50}s of 8.72 and 5.15 μM, respectively in cell assay.



Purity: 99.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 5 g, 10 g

Neochlorogenic acid

(trans-5-O-Caffeoylquinic acid)

Cat. No.: HY-N0722

Neochlorogenic acid is a natural polyphenolic compound found in dried fruits and other plants. Neochlorogenic acid inhibits the production of **TNF-α** and **IL-1β**. Neochlorogenic acid suppresses **iNOS and COX-2** protein expression.



Purity: 99.07%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Nepafenac

(AHR 9434; AL 6515)

Cat. No.: HY-17357

Nepafenac(AHR 9434; AL 6515; Nevanac) is a selective COX-2 inhibitor; is prodrug of Amfenac. IC50 value: Target: COX-2 Nepafenac is a NSAID (nonsteroidal anti inflammatory drug) that is routinely used in opthamology to control pain following cataract surgery.



Purity: 99.51%
Clinical Data: Launched
Size: 10 mM × 1 mL, 25 mg, 100 mg

Nepafenac-d5

(AHR-9434-d5; AL-6515-d5)

Cat. No.: HY-17357S

Nepafenac D5 (AHR-9434 D5) is the deuterium labeled Nepafenac, which is a selective COX-2 inhibitor.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Nimesulide

(R805)

Cat. No.: HY-B0363

Nimesulide is a selective **COX-2** inhibitor, with IC_{50}s of 70 nM-70 μM in a time-dependent manner, but it shows no effect on COX-1 (IC_{50} >100 μM). Nimesulide has potent anti-inflammatory, analgesic and antipyretic properties.



Purity: 99.70%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Nimesulide D5

Cat. No.: HY-B0363S

Nimesulide D5 is a deuterium labeled Nimesulide. Nimesulide is a selective **COX-2** inhibitor, with IC_{50}s of 70 nM-70 μM in a time-dependent manner, but it shows no effect on COX-1 (IC_{50} >100 μM). Nimesulide has potent anti-inflammatory, analgesic and antipyretic properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Nitroaspirin

(NCX 4016)

Cat. No.: HY-123823

Nitroaspirin (NCX 4016) is a nitric oxide (NO) donor and a nitro-derivative of Aspirin, which combines with Nitroaspirin to inhibit cyclooxygenase.



Purity: >98%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 50 mg, 100 mg

Nitroflurbiprofen

(HCT 1206; NO-flurbiprofen; Nitroxybutyl flurbiprofen)

Cat. No.: HY-U00013

Nitroflurbiprofen is a **cyclooxygenase** (**COX**) inhibitor with nitric oxide (NO)-donating properties, modulates the increased intrahepatic vascular tone in portal hypertensive cirrhotic rats.



Purity: 99.64%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

NS-398

Cat. No.: HY-13913

NS-398 is a non-steroidal an-inflammatory agent with analgesic and antipyretic effects, and selectively inhibits prostaglandin G/H synthase 2/cyclooxygenase 2 (**COX-2**) activity, with an IC_{50} of 3.8 μM, and has no effect on COX-1 at 100 μM.



Purity: 98.70%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Ocarocoxib

Cat. No.: HY-139578

Ocarocoxib, a potent **COX-2 (cyclooxygenase-2)** inhibitor, is a non-steroidal anti-inflammatory for veterinary use.



Purity: 99.94%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Otenaproxesul

(ATB-346) Cat. No.: HY-15028

Otenaproxesul (ATB-346), an orally active non-steroidal anti-inflammatory drug (**NSAID**), inhibits **cyclooxygenase-1 and 2 (COX-1 and 2)**. Otenaproxesul possesses antiinflammatory and antinociceptive activities.



Purity: 98.35%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Oxaprozin

(Oxaprozinum; Wy21743) Cat. No.: HY-B0808

Oxaprozin is an inhibitor of both **COX-1** and **COX-2** with IC_{50}s of 2.2 μM and 36 μM for human platelet COX-1 and IL-1-stimulated human synovial cell COX-2, respectively. Oxaprozin also inhibits the activation of **NF-κB**.



Purity: 99.76%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Oxaprozin D4

(Wy-21743 D4) Cat. No.: HY-B0808S

Oxaprozin D4 (Wy-21743 D4) is the deuterium labeled Oxaprozin, which is a non-steroidal anti-inflammatory agent (NSAID).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Oxaprozin-d5

(Oxaprozinum-d5; Wy21743-d5) Cat. No.: HY-B0808S1

Oxaprozin-d5 is deuterium labeled Oxaprozin. Oxaprozin is an inhibitor of both COX-1 and COX-2 with IC50s of 2.2 μM and 36 μM for human platelet COX-1 and IL-1-stimulated human synovial cell COX-2, respectively. Oxaprozin also inhibits the activation of NF-κB.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Oxyphenbutazone

Cat. No.: HY-B1355A

Oxyphenbutazone is a phenylbutazone derivative, with anti-inflammatory effect. Oxyphenbutazone is a non-selective **COX** inhibitor. Oxyphenbutazone selectively kills non-replicating Mycobaterium tuberculosis.



Purity: 98.07%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg

Oxyphenbutazone-d9

Cat. No.: HY-B1355AS

Oxyphenbutazone-d9 is the deuterium labeled Oxyphenbutazone. Oxyphenbutazone is a phenylbutazone derivative, with anti-inflammatory effect. Oxyphenbutazone is a non-selective **COX** inhibitor. Oxyphenbutazone selectively kills non-replicating Mycobaterium tuberculosis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Pamicogrel

(KBT3022) Cat. No.: HY-U00175

Pamicogrel (KBT3022) is a **cyclooxygenase** (**COX**) inhibitor.



Purity: 99.44%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Paradol

([6]-Gingerone; [6]-Paradol) Cat. No.: HY-14617

Paradol is a pungent phenolic substance found in ginger and other Zingiberaceae plants. Paradol is an effective inhibitor of tumor promotion in mouse skin carcinogenesis, binds to **cyclooxygenase (COX)-2** active site.



Purity: 99.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Parecoxib

(SC 69124) Cat. No.: HY-17474

Parecoxib (SC 69124) is a highly selective and orally active **COX-2** inhibitor, the prodrug of Valdecoxib (HY-15762). Parecoxib Sodium is a nonsteroidal anti-inflammatory agent (NSAID) and inhibits prostaglandin (PG) synthesis.



Purity: 98.34%
Clinical Data: Launched
Size: 10 mM × 1 mL, 25 mg, 50 mg, 100 mg

Parecoxib Sodium

(SC 69124A) Cat. No.: HY-17474A

Parecoxib Sodium (SC 69124A) is a highly selective and orally active **COX-2** inhibitor, the prodrug of Valdecoxib (HY-15762). Parecoxib Sodium is a nonsteroidal anti-inflammatory agent (NSAID) and inhibits prostaglandin (PG) synthesis.



Purity: 99.97%
Clinical Data: Launched
Size: 10 mM × 1 mL, 25 mg, 50 mg, 100 mg

Parecoxib-d5 sodium

(SC 69124A-d5)

Cat. No.: HY-17474AS

Parecoxib-d5 sodium (SC 69124A-d5) is the deuterium labeled Parecoxib sodium. Parecoxib Sodium (SC 69124A) is a highly selective and orally active **COX-2** inhibitor, the prodrug of Valdecoxib (HY-15762).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pectolinarigenin

Cat. No.: HY-N0493

Pectolinarigenin is a dual inhibitor of **COX-2/5-LOX**. Anti-inflammatory activity. Pectolinarigenin has potent inhibitory activities on melanogenesis.



Purity: 99.47%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Pelubiprofen

Cat. No.: HY-12383

Pelubiprofen, an orally active and non-steroidal anti-inflammatory drug, is a member of the 2-arylpropionic acid family and has relatively selective effects on **COX-2** activity.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Pelubiprofen-13C,d3

Cat. No.: HY-12383S

Pelubiprofen-13C,d3 is the 13C- and deuterium labeled. Pelubiprofen, an orally active and non-steroidal anti-inflammatory drug, is a member of the 2-arylpropionic acid family and has relatively selective effects on COX-2 activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pentagamavunon-1

(PGV-1)

Cat. No.: HY-136477

Pentagamavunon-1 (PGV-1), a Curcumin analog with oral activity, targets on several molecular mechanisms to induce **apoptosis** including inhibition of angiogenic factors cyclooxygenase-2 (**COX-2**) and vascular endothelial growth factor (**VEGF**). PGV-1 inhibits **NF-κB** activation.



Purity: 99.80%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Peonidin chloride

(YGM-6 chloride)

Cat. No.: HY-N2459

Peonidin chloride is an O-methylated anthocyanidin that functions as a primary plant pigment, endowing purplish-red hues to flowers such as the peony, from which it takes its name, as well as berries and vegetables.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

Phenacetin

(Acetophenetidin)

Cat. No.: HY-B0476

Phenacetin (Acetophenetidin) is a non-opioid analgesic/antipyretic agent. Phenacetin is a selective **COX-3** inhibitor. Phenacetin is used as probe of cytochrome P450 enzymes CYP1A2 in human liver microsomes and in rats.



Purity: 99.54%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Phenacetin-d5

(Acetophenetidin-d5)

Cat. No.: HY-B0476S

Phenacetin-d5 (Acetophenetidin-d5) is the deuterium labeled Phenacetin. Phenacetin (Acetophenetidin) is a non-opioid analgesic/antipyretic agent. Phenacetin is a selective **COX-3** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 2.5 mg, 25 mg

Phenethyl ferulate

Cat. No.: HY-W009248

Phenethyl ferulate is a major constituent ofQianghuo, shows inhibitory activity against **cyclooxygenase** (**COX**) and **5-lipoxygenase** (**5-LOX**) with IC_{50} values of 4.35 μM and 5.75 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Phenidone

Cat. No.: HY-W010144

Phenidone, an orally active dual inhibitor of **cyclooxygenase (COX)** and **lipoxygenase (LOX)**, ameliorates rat paralysis in experimental autoimmune encephalomyelitis. Phenidone is a potent hypotensive agent in the spontaneously hypertensive rat.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg

Phenylbutazone

Cat. No.: HY-B0230

Phenylbutazone is an efficient reducing cofactor for the peroxidase activity of prostaglandin H synthase (PHS). Phenylbutazone, a hepatotoxin, is a nonsteroidal anti-inflammatory drug (NSAID).



Purity: 99.94%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg

Phenylbutazone(diphenyl-d10)

Cat. No.: HY-B0230S

Phenylbutazone-d10 (diphenyl) is the deuterium labeled Phenylbutazone. Phenylbutazone is an efficient reducing cofactor for the peroxidase activity of prostaglandin H synthase (PHS). Phenylbutazone, a hepatotoxin, is a nonsteroidal anti-inflammatory drug (NSAID).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg, 10 mg, 25 mg

Phenylbutazone-d9

Cat. No.: HY-B0230S1

Phenylbutazone-d9 is the deuterium labeled Phenylbutazone. Phenylbutazone is an efficient reducing cofactor for the peroxidase activity of prostaglandin H synthase (PHS). Phenylbutazone, a hepatotoxin, is a nonsteroidal anti-inflammatory drug (NSAID).



Purity: >98%
Clinical Data: No Development Reported
Size: 2.5 mg, 25 mg

Piroxicam

(CP-16171)

Cat. No.: HY-B0253

Piroxicam (CP-16171) is a non-steroidal anti-inflammatory drugs, acts as a **COX** inhibitor, with **IC_{50}**s of 47, 25 μM for human monocyte COX-1 and COX-2, respectively.



Purity: 99.61%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g, 10 g

Piroxicam D3

(CP-16171 D3)

Cat. No.: HY-B0253S

Piroxicam D3 (CP-16171 D3) is deuterium labeled Piroxicam. Piroxicam is a non-steroidal anti-inflammatory drugs, acts as a COX inhibitor, with IC_{50}s of 47, 25 μM for human monocyte COX-1 and COX-2, respectively .



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Piroxicam-d4

(CP-16171-d4)

Cat. No.: HY-B0253S1

Piroxicam-d4 (CP-16171-d4) is the deuterium labeled Piroxicam. Piroxicam (CP-16171) is a non-steroidal anti-inflammatory drugs, acts as a **COX** inhibitor, with **IC_{50}**s of 47, 25 μM for human monocyte COX-1 and COX-2, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Plantanone B

(Kaempferol 3-O-rhamnosylgentiobioside)

Cat. No.: HY-N8167

Plantanone B is a moderate **antioxidant-agent** with an IC_{50} of 169.8±5.2 μM. Plantanone B shows significant ovine COX-1 and moderate COX-2 inhibitory activities. Plantanone B has the potential for inflammation-related diseases research.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Polmacoxib

(CG100649)

Cat. No.: HY-16726

Polmacoxib (CG100649) is a first-in-class, orally active nonsteroidal anti-inflammatory drug (NSAID) which is a dual inhibitor of **COX-2** (IC_{50} around 0.1 μg/ml) and **carbonic anhydrase**. Polmacoxib inhibits colorectal adenoma and tumor growth in mouse models.



Purity: 99.70%
Clinical Data: Launched
Size: 5 mg, 10 mg, 25 mg

Pranoprofen

Cat. No.: HY-B0336

Pranoprofen is a non-steroidal anti-inflammatory agent (**NSAID**) for the research of keratitis or other ophthalmology diseases. Pranoprofen inhibit **COX-1** and **COX-2** enzymes, thus blocking arachidonic acid converted to eicosanoids and reducing prostaglandins synthesis.



Purity: 99.37%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Prim-O-glucosylcimifugin

Cat. No.: HY-N0635

Prim-O-glucosylcimifugin exerts anti-inflammatory effects through the inhibition of **iNOS** and **COX-2** expression by through regulating JAK2/STAT3 signaling.



Purity: 99.79%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Propacetamol

Cat. No.: HY-145453

Propacetamol is a water-soluble acetaminophen precursor drug, which can be administered via non intestinal route. It is an analgesic used to treat postoperative pain, acute trauma and gastrointestinal disorders.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Propyphenazone

(4-Isopropylantipyrine; Isopropylphenazone)

Cat. No.: HY-A0273

Propyphenazone is a pyrazolone derivative with anti-inflammatory, analgesic and antipyretic activity, Propyphenazone-based analogues as prodrugs and selective cyclooxygenase-2 inhibitors.



Purity: 99.94%
Clinical Data: Launched
Size: 10 mM × 1 mL, 250 mg

Propyphenazone-d3

Cat. No.: HY-A0273S

Propyphenazone-d3 is the deuterium labeled Propyphenazone. Propyphenazone is a pyrazolone derivative with anti-inflammatory, analgesic and antipyretic activity, Propyphenazone-based analogues as prodrugs and selective cyclooxygenase-2 inhibitors.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Psoralidin

Cat. No.: HY-N0232

Psoralidin is a dual inhibitor of **COX-2** and **5-LOX**, regulates ionizing radiation (IR)-induced pulmonary inflammation.Anti-cancer, anti-bacterial, and anti-inflammatory properties. Psoralidin significantly downregulates **NOTCH1** signaling.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

PTUPB

Cat. No.: HY-122591

PTUPB is a potent and dual **sEH** and **COX-2** enzymes inhibitor with IC_{50} of 0.9 nM and 1.26 μM, respectively.</br>.



Purity: 98.82%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Rebamipide

(OPC12759; Proamipide)

Cat. No.: HY-B0360

Rebamipide (OPC12759) is a mucoprotective agent. Rebamipide induces **COX-2** expression, increases **PGE2** levels, and enhances gastric mucosal defense in a COX-2-dependent manner.



Purity: 99.88%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Rebamipide mofetil

Cat. No.: HY-109158

Rebamipide mofetil is an orally active prodrug of Rebamipide (OPC12759). Rebamipide is a mucoprotective agent. Rebamipide induces **COX-2** expression, increases PGE2 levels, and enhances gastric mucosal defense in a COX-2-dependent manner.



Purity: 98.02%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Rebamipide-d4

(OPC12759-d4; Proamipide-d4)

Cat. No.: HY-B0360S

Rebamipide D4 (OPC12759 D4) is deuterium labeled Rebamipide. Rebamipide is a mucoprotective agent. Rebamipide induces **COX-2** expression, increases **PGE2** levels, and enhances gastric mucosal defense in a COX-2-dependent manner.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Regaloside B

Cat. No.: HY-N7688

Regaloside B is a phenylpropanoid isolated from Lilium longiflorum. Regaloside B can inhibit the expression of **iNOS** and **COX-2**. Regaloside B has anti-inflammatory activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Rehmapicrogenin

Cat. No.: HY-N7630

Rehmapicrogenin, isolated from the root of Rehmannia glutinosa, exhibits potent anti-inflammatory effect by inhibiting iNOS, COX-2 and IL-6.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Revaprazan hydrochloride

Cat. No.: HY-N7067

Revaprazan hydrochloride is a novel acid pump antagonist (**APA**). Revaprazan hydrochloride reduces **COX-2** expression and has significant anti-inflammatory actions activities in H. pylori infection.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

RHC 80267

(U-57908)

Cat. No.: HY-107416

RHC 80267 (U-57908) is a potent and selective inhibitor of **diacylglycerol lipase (DAGL)** (with IC_{50} of 4 μM in canine platelets). RHC-80267 inhibits **cholinesterase** activity with an IC_{50} of 4 μM, thereby enhancing the relaxation evoked by **acetylcholine**.



Purity: 99.51%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg, 50 mg, 100 mg

Roburic acid

Cat. No.: HY-N0481

Roburic acid, a tetracyclic triterpenoid found in Gentiana macrophylla, acts as an inhibitor of **COX**, with IC_{50}s of 5 and 9 μM for COX-1 and COX-2, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Rofecoxib

(MK 966)

Cat. No.: HY-17372

Rofecoxib is a potent, specific and orally active **COX-2** inhibitor, with IC_{50}s of 26 and 18 nM for human COX-2 in human osteosarcoma cells and Chinese hamster ovary cells, with a 1000-fold selectivity for COX-2 over human COX-1 (IC_{50} > 50 μM in U937 cells and > 15 μM in...



Purity: 99.91%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Rofecoxib-d5

Cat. No.: HY-17372S

Rofecoxib D5 (MK 966 D5) is the deuterium labeled Rofecoxib.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Rutaecarpine

(Rutecarpine)

Cat. No.: HY-N0147

Rutaecarpine, an alkaloid of Evodia rutaecarpa, is an inhibitor of **COX-2** with an IC_{50} value of 0.28 μM.



Purity: 98.11%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

RWJ 63556

Cat. No.: HY-U00022

RWJ 63556 is an orally active **COX-2 selective/5-lipoxygenase** inhibitor, with anti-inflammatory activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

S-(+)-Ketoprofen

((S)-Ketoprofen; Dexketoprofen)

Cat. No.: HY-B2137

S-(+)-Ketoprofen is a potent inhibitor of both **COX-1** and **COX-2** with IC_{50}s of 1.9 and 27 nM, respectively.



Purity: 99.93%
Clinical Data: Phase 4
Size: 10 mM × 1 mL, 100 mg

S-(+)-Marmesin

((+)-Marmesin; (S)-Marmesin)

Cat. No.: HY-N2176

S-(+)-Marmesin is a natural coumarin, exhibiting **COX-2/5-LOX** dual inhibitory activity.



Purity: 99.11%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

S-2474

Cat. No.: HY-19212

S-2474 is an inhibitor of **COX-2** and **5-lipoxygenase (5-LO)**, with IC_{50}s of 11 nM and 27 μM for COX-2 and COX-1 in human intact cells, and used as a nonsteroidal anti-inflammatory drug.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

S-Diclofenac

(ACS 15; ATB-337) Cat. No.: HY-15035

S-Diclofenac is a hybrid molecule of an H_2S donor and the NSAID diclofenac. S-Diclofenac spares the gastric mucosa of injury despite markedly suppressing prostaglandin synthesis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Salicin

(D-(−)-Salicin; Salicoside) Cat. No.: HY-N0149

Salicin is a natural **COX** inhibitor.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Salicylic acid

(2-Hydroxybenzoic acid) Cat. No.: HY-B0167

Salicylic acid (2-Hydroxybenzoic acid) inhibits cyclo-oxygenase-2 (**COX-2**) activity independently of transcription factor (NF-κB) activation.



Purity: 96.22%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 10 g, 50 g

Salicylic acid-d6

(2-Hydroxybenzoic acid-d6) Cat. No.: HY-B0167S

Salicylic acid-D6 (2-Hydroxybenzoic acid-D6) is a deuterium labeled Salicylic acid. Salicylic acid inhibits cyclo-oxygenase-2 (**COX-2**) activity independently of transcription factor (NF-κB) activation.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

SC-236

Cat. No.: HY-W010983

SC-236 is an orally active **COX-2** specific inhibitor (IC_{50} = 10 nM) and a **PPARγ** agonist. SC-236 suppresses activator protein-1 (**AP-1**) through c-Jun NH2-terminal kinase. SC-236 exerts anti-inflammatory effects by suppressing phosphorylation of ERK in a murine model.



Purity: 99.45%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SC-560

Cat. No.: HY-59105

SC-560 is a potent and selective **COX-1** inhibitor with an IC_{50} of 9 nM.



Purity: 99.80%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

SC-58125

Cat. No.: HY-W013164

SC-58125 is a potent and selective inhibitor of **cyclooxygenase 2 (COX-2)**, with an IC_{50} of 0.04 μM. SC-58125 exhibits antitumor activity in vitro and in vivo. SC-58125 also can inhibit edema at the inflammatory site and has analgesic effect.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SC57666

Cat. No.: HY-U00129

SC57666 is a selective **COX2** inhibitor with an IC_{50} of 26 nM.



Purity: 98.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg

SC58451

Cat. No.: HY-U00239

SC58451 is a potent and selective **Cox-2** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sodium Salicylate (Salicylic acid sodium salt; 2-Hydroxybenzoic acid sodium salt)

Cat. No.: HY-B0167A

Sodium Salicylate (Salicylic acid sodium salt) inhibits cyclo-oxygenase-2 (**COX-2**) activity independently of transcription factor (NF-κB) activation. Sodium Salicylate is also a **S6K** inhibitor.



Purity: 99.88%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 10 g, 50 g

Sphondin

Cat. No.: HY-N2429

Sphondin possesses an inhibitory effect on IL-1β-induced increase in the level of **COX-2** protein and PGE_2 release in A549 cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Sudoxicam

Cat. No.: HY-106628

Sudoxicam is a reversible and orally active **COX** antagonist and a non-steroidal anti-inflammatory drug (NSAID) from the enol-carboxamide class. Sudoxicam has potent anti-inflammatory, anti-edema and antipyretic activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Sulindac

(MK-231)

Cat. No.: HY-B0008

Sulindac (MK-231) is a non-steroidal antiinflammatory agent, acts as a **COX-2** inhibitor, and inhibits overexpression of COX-2.



Purity: 99.81%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Sulindac-d3

(MK-231-d3)

Cat. No.: HY-B0008S

Sulindac-d3 is deuterium labeled Sulindac. Sulindac (MK-231) is a non-steroidal antiinflammatory agent, acts as a COX-2 inhibitor, and inhibits overexpression of COX-2.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Syringaldehyde

Cat. No.: HY-N1390

Syringaldehyde is a polyphenolic compound belonging to the group of flavonoids and is found in different plant species like Manihot esculenta and Magnolia officinalis. Syringaldehyde moderately inhibits **COX-2** activity with an IC_{50} of 3.5 μg/mL.



Purity: 99.96%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Taraxerol acetate

Cat. No.: HY-N2599

Taraxerol acetate is a **COX-1** and **COX-2** inhibitor with IC_{50} values of 116.3 μM and 94.7 μM, respectively. Taraxerol acetate the has the anticancer potential and induces cell **apoptosis**.</br>.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tazofelone

(LY 213829)

Cat. No.: HY-137789

Tazofelone (LY 213829) is a cyclooxygenase-II (COX-II) inhibitor. Tazofelone transform into sulfoxide and quinol metabolites is primarily mediated by CYP3A. Tazofelone can be used for the research of inflammatory bowel disease.



Purity: 98.89%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

Tenidap

(CP-66248)

Cat. No.: HY-105028

Tenidap, a non-steroidal anti-inflammatory drug, is a selective **COX-1** inhibitor, with IC_{50} values of 0.03 μM and 1.2 μM for COX-1 and COX-2, respectively. Tenidap has anti-inflammatory and antirheumatic properties. Tenidap is also a specific SLC26A3 inhibitor.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Tenidap-d3

(CP-66248-d3)

Cat. No.: HY-105028S

Tenidap-d3 (CP-66248-d3) is the deuterium labeled Tenidap. Tenidap, a non-steroidal anti-inflammatory drug, is a selective **COX-1** inhibitor, with IC_{50} values of 0.03 μM and 1.2 μM for COX-1 and COX-2, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tenoxicam

(Ro-12-0068)

Cat. No.: HY-B0440

Tenoxicam (Ro-12-0068), an antiinflammatory agent with analgesic and antipyretic properties.



Purity: 99.94%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg

Tepoxalin

Cat. No.: HY-13219

Tepoxalin is a dual inhibitor of COX and 5-lipoxygenase (5-LO) with potent anti-inflammatory activity and a favorable gastrointestinal profile.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Teriflunomide impurity 3

(4-Amino-N-(4-trifluoromethylphenyl)benzamide)

Cat. No.: HY-134753

Teriflunomide impurity 3 (4-Amino-N-(4-trifluoromethylphenyl)benzamide) is a selective **COX-1** inhibitor with an IC_{50} of 30 μM. Teriflunomide impurity 3 is less active against COX-2 (IC_{50}>100 μM).



Purity: 99.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TFAP

(N-(5-Aminopyridin-2-yl)-4-(trifluoromethyl)benzamide)

Cat. No.: HY-112731

TFAP is a selective cyclooxygenase-1 **(COX-1)** inhibitor, with an IC_{50} of 0.8 μM.



Purity: 99.71%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Thioflosulide

(L-745337)

Cat. No.: HY-19217

Thioflosulide (L-745337) is a selective **cyclooxygenase-2 (COX2)** inhibitor, with an IC_{50} of 2.3 nM, and shows anti-inflammatory activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tiaprofenic acid

Cat. No.: HY-106579

Tiaprofenic acid is an orally active nonsteroidal anti-inflammatory drug **(NSAID)** with anti-inflammatory and analgesic potency. Tiaprofenic acid inhibits prostaglandin synthesis by suppressing **cyclo-oxygenase (COX)**.



Purity: 99.33%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg

Tilmacoxib

(JTE522; JTP19605; RWJ57504)

Cat. No.: HY-U00197

Tilmacoxib (JTE522) is a highly selective, time-dependent and irreversible human **COX-2** inhibitor with an IC_{50} of 85 nM in an enzyme assay.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 1 mg

Timegadine

(SR1368)

Cat. No.: HY-100125

Timegadine, a new antiinflammatory agent, is found to be a potent, competitive inhibitor of **cyclo-oxygenase** (**COX**) and **lipo-oxygenase**, with IC_{50}s ranging from 5 nM (washed rabbit platelets) to 20 μM (rat brain) for COX and 100 μM for lipo-oxygenase both in the cytosol fraction...



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tolfenamic Acid

(GEA 6414)

Cat. No.: HY-B0335

Tolfenamic Acid (GEA 6414) is a non-steroidal anti-inflammatory and anti-cancer agent, selectively inhibits **COX-2**, with an IC_{50} of 13.49 μM (3.53 μg/mL) in LPS-treated (COX-2) canine DH82 monocyte/macrophage cells, but shows no effect on COX-1.



Purity: 99.56%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 10 g

Tolfenamic Acid-D4

Cat. No.: HY-B0335S

Tolfenamic Acid-D4 (GEA 6414-D4) is the deuterium labeled Tolfenamic Acid.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tolmetin

Cat. No.: HY-B1799

Tolmetin is an orally active and potent **COX** inhibitor with IC_{50}s of 0.35 μM and 0.82 μM human COX-1 and COX-2, respectively. Tolmetin is a non-steroidal anti-inflammatory drug (NSAID).



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 25 mg

Tolmetin sodium dihydrate

Cat. No.: HY-B1489

Tolmetin sodium dihydrate is an orally active and potent **COX** inhibitor with IC_{50}s of 0.35 μM and 0.82 μM human COX-1 and COX-2, respectively. Tolmetin sodium dihydrate is a non-steroidal anti-inflammatory drug (NSAID).



Purity: 99.89%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Tolmetin-d3

Cat. No.: HY-B1799S

Tolmetin-d3 is the deuterium labeled Tolmetin. Tolmetin is an orally active and potent **COX** inhibitor with IC_{50}s of 0.35 μM and 0.82 μM human COX-1 and COX-2, respectively. Tolmetin is a non-steroidal anti-inflammatory drug (NSAID).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Triflusal

Cat. No.: HY-B0531

Triflusal irreversibly inhibits the production of thromboxane-B2 in platelets by acetylating cycloxygenase-1. Target: COX Triflusal at 10 mM, 100 mM and 1 M decreases LDH efflux in rat brain slices after anoxia/reoxygenation by 24%, 35% and 49% respectively.



Purity: 99.64%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Triflusal-d3

Cat. No.: HY-B0531S

Triflusal-d3 is deuterium labeled Triflusal.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Valdecoxib

(SC 65872)

Cat. No.: HY-15762

Valdecoxib is a highly potent and selective inhibitor of **COX-2**, with IC_{50}s of 5 nM and 140 μM for COX-2 and COX-1, respeceively. Valdecoxib can be used in the research of arthritis and pain.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Valdecoxib-d3

(SC 65872-d3)

Cat. No.: HY-15762S

Valdecoxib-d3 (SC 65872-d3) is the deuterium labeled Valdecoxib. Valdecoxib is a highly potent and selective inhibitor of **COX-2**, with IC_{50}s of 5 nM and 140 μM for COX-2 and COX-1, respeceively. Valdecoxib can be used in the research of arthritis and pain.



Purity: >98%
Clinical Data: No Development Reported
Size: 2.5 mg, 10 mg, 25 mg

Vedaprofen

(Quadrisol; CERM 10202; PM 150)

Cat. No.: HY-118827

Vedaprofen (Quadrisol) is a **COX-1** selective nonsteroidal anti-inflammatory drug (NSAID) for serum **TxB2** and exudate **PGE2** inhibition . Vedaprofen is a Escherichia coli (E. coli) sliding clamp (SC) inhibitor with the IC_{50} of 222 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Vedaprofen-d3

Cat. No.: HY-118827S

Vedaprofen-d3 is the deuterium labeled Vedaprofen. Vedaprofen (Quadrisol) is a **COX-1** selective nonsteroidal anti-inflammatory drug (NSAID) for serum **TxB2** and exudate **PGE2** inhibition . Vedaprofen is a Escherichia coli (E. coli) sliding clamp (SC) inhibitor with the IC_{50} of 222 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Veratric acid

(3,4-Dimethoxybenzoic acid)

Cat. No.: HY-N2007

Veratric acid (3,4-Dimethoxybenzoic acid) is an orally active phenolic compound derived from vegetables and fruits, has antioxidant and anti-inflammatory activities.



Purity: 99.99%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Veratric acid-d6

(3,4-Dimethoxybenzoic acid-d6)

Cat. No.: HY-N2007S

Veratric acid-d6 is deuterium labeled Veratric acid. Veratric acid (3,4-Dimethoxybenzoic acid) is an orally active phenolic compound derived from vegetables and fruits, has antioxidant and anti-inflammatory activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Xanthohumol

Cat. No.: HY-N1067

Xanthohumol is one of the principal flavonoids isolated from hops, the inhibitor of diacylglycerol acetyltransferase (**DGAT**), **COX-1** and COX-2, and shows anti-cancer and anti-angiogenic activities.



Purity: 99.84%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Zaltoprofen

(CN100)

Cat. No.: HY-B0619

Zaltoprofen (CN100), a non-steroidal anti-inflammatory drug (NSAID), is a preferential and orally active **COX-2** inhibitor, with IC_{50}s of 1.3 and 0.34 μM for **COX-1** and **COX-2**, respectively.



Purity: 99.65%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Zaltoprofen-13C,d3

Cat. No.: HY-B0619S1

Zaltoprofen-13C,d3 is the 13C- and deuterium labeled. Zaltoprofen (CN100), a non-steroidal anti-inflammatory drug (NSAID), is a preferential and orally active COX-2 inhibitor, with IC50s of 1.3 and 0.34 μM for COX-1 and COX-2, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Zaltoprofen-d7

Cat. No.: HY-B0619S

Zaltoprofen-d7 is the deuterium labeled Zaltoprofen. Zaltoprofen (CN100), a non-steroidal anti-inflammatory drug (NSAID), is a preferential and orally active **COX-2** inhibitor, with IC_{50}s of 1.3 and 0.34 μM for **COX-1** and **COX-2**, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

[10]-Shogaol

Cat. No.: HY-N2434

[10]-Shogaol is an antioxidant from Zingiber officinale for human skin cell growth and a migration enhancer. [10]-Shogaol inhibits COX-2 with an IC_{50} of 7.5 μM and has antiproliferation activity.



Purity: 99.78%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

[8]-Shogaol

Cat. No.: HY-N2435

-Shogaol, one of the pungent phenolic compounds in ginger, exhibits anti-platelet activity (IC_{50}=5 μM) and inhibits COX-2 (IC_{50}=17.5 μM). -Shogaol induces apoptosis in human leukemia cells.



Purity: 99.93%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

α-Humulene

(Humulene; α-Caryophyllene)

Cat. No.: HY-N6968

α-Humulene is a main constituent of Tanacetum vulgare L. (Asteraceae) essential oil with anti-inflammation (IC_{50}=15±2 μg/mL). α-Humulene inhibits **COX-2** and **iNOS** expression.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

α-Spinasterol

Cat. No.: HY-N6962

α-Spinasterol, isolated from Spinacia oleracea, has antibacterial activity. α-Spinasterol is a transient receptor potential vanilloid 1 (**TRPV1**) antagonist, has anti-inflammatory, antidepressant, antioxidant and antinociceptive effects.



Purity: 99.15%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

α-Chaconine

Cat. No.: HY-129113

α-Chaconine inhibits the expressions of **COX-2**, **IL-1β**, **IL-6**, and **TNF-α** at the transcriptional level. α-Chaconine inhibits the LPS-induced expressions of **iNOS** and **COX-2** at the protein and mRNA levels and their promoter activities in RAW 264.7 macrophages. Anti-inflammatory effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

β-Elemonic acid

Cat. No.: HY-N2454

β-Elemonic acid is a triterpene isolated from Boswellia papyrifera. β-Elemonic acid induces cell **apoptosis**, reactive oxygen species (**ROS**) and **COX-2** expression and inhibits **prolyl endopeptidase**. β-Elemonic acid exhibits anticancer and anti-inflammatory effects.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

γ-Tocopherol

(D-γ-Tocopherol; (+)-γ-Tocopherol)

Cat. No.: HY-N7148

γ-Tocopherol (D-γ-Tocopherol) is a potent **cyclooxygenase (COX)** inhibitor. γ-Tocopherol is a naturally occurring form of Vitamin E in many plant seeds, such as corn oil and soybeans. γ-Tocopherol possesses antiinflammatory properties and anti-cancer activity.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

γ-Tocopherol-d4

Cat. No.: HY-N7148S1

γ-Tocopherol-d4 (D-γ-Tocopherol-d4) is the deuterium labeled γ-Tocopherol. γ-Tocopherol (D-γ-Tocopherol) is a potent **cyclooxygenase (COX)** inhibitor. γ-Tocopherol is a naturally occurring form of Vitamin E in many plant seeds, such as corn oil and soybeans.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg